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ABSTRACT
Inflammation in hypertrophic adipose tissue is a critical inducer of adipose tissue 
dysfunction, which ultimately leads to systemic insulin resistance and type 2 diabetes. 
Elevation of lipopolysaccharide (LPS) induced by high fat diet has been recently 
proposed to be one of the potential mechanisms contributing to the development of 
inflammation and metabolic dysfunction of adipose tissue in obesity. Therefore, it is of 
interest to expand our understanding of LPS effect on adipocyte metabolism and to 
identify the molecular mechanism by which LPS deteriorates adipose tissue metabolism.
In the first study, we investigated the effect of LPS on the adipogenic capacity and 
cellular senescence of adipocyte progenitors by using stromal-vascular (SV) cells isolated 
from inguinal adipose tissue of C57BL/6 mice. We found that LPS treatment for 24-hour
prior to the induction of differentiation led to the inhibition of adipogenesis. In addition, 
LPS induced features of premature senescence of SV cells. Further studies showed that 
LPS treatment caused a reduction in Zfp423 and PPARγ expression in SV cells, 
suggesting that LPS impairs pre-adipocyte differentiation. In the second study, we 
explored the role of endosomal/lysosomal protein NPC2 (Niemann-Pick disease, Type 
C2) in regulating lysosomal activity and in mediating LPS effect on adipocyte 
inflammation and function. NPC2 knockdown reduced lysosomal protease cathepsin B
levels and impaired autophagy-lysosomal activity in 3T3-L1 adipocytes. Interestingly, 
NPC2 knockdown diminished LPS effect on inflammatory response and blunted LPS-
induced glucose uptake in adipocytes. In the third study, we determined the effect of 
eicosapentaenoic acid (EPA) on promoting metabolic health of adipocytes, specifically 
the browning of subcutaneous white adipocytes. When added to SV cell cultures during 
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8-day adipocyte differentiation, EPA significantly increased the expression of 
thermogenic genes as well as mitochondrial DNA content. These results indicate that 
EPA enhances energy expenditure capacity by recruiting beige adipocytes. In summary, 
we have demonstrated a new mechanism by which LPS disrupts adipogenesis and 
adipocyte metabolism. We have also characterized the role of NPC2 as an important 
molecular mediator of LPS-induced adipocyte inflammation and the effect of EPA on 
promoting the browning of subcutaneous adipocytes. 
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1CHAPTER 1
LITERATURE REVIEW
Ming Zhao wrote this chapter.
2The prevalence of obesity has been increasing dramatically and globally in the 
last decades [1]. It’s very likely that the global rates of adulthood obesity will be 
continuously increased in the future. The rising incidence clearly maintains the obesity as 
a top health concern since adulthood obesity, especially abdominal obesity, is well-
established as a risk factor for a series of diseases, including cardiovascular disease 
(CVD), type 2 diabetes (T2D), nonalcoholic fatty liver disease (NAFLD), and some types 
of cancer [2]. 
Type 2 diabetes (T2DM) is now affecting over 20 million Americans and 
predicted to be the leading killer by 2050 [3]. People with uncontrolled insulin resistance 
will progress to T2DM, which largely increases the risk of diabetic complications such as 
cardiovascular disease, lower limb amputations, non-traumatic blindness, and kidney 
failure. Among insulin responsive tissues/organs, such as liver, skeletal muscle and 
adipose tissue, adipose tissue is believed to play a central role in the regulation of 
systemic insulin sensitivity [4]. Adipose tissue is the major site of lipid metabolism and 
adipokines/cytokine production. Adipose tissue dysfunction, which occurs in obesity, is 
the major contributor to obesity-associated metabolic complications such as hypertension, 
cardiovascular disease, inflammation, insulin resistance and type 2 diabetes. 
31. Role of adipose tissue in metabolism
1.1 White adipose tissue (WAT)
It has long been known that white adipose tissue (WAT) plays a crucial role in 
regulating energy metabolism and insulin sensitivity. WAT is the main storage site of 
excess energy derived from food [5]. Dietary energy from glucose and lipids are stored 
mostly in a single large lipid droplet in the form of triglyceride in white adipocytes. 
During starvation or exercise, stored triglycerides are rapidly hydrolyzed and fatty acids 
are released as an energy source and transported to other tissues for oxidation. More 
importantly, adipose tissue has been recognized as an endocrine organ, and it secretes 
multiple biologically active peptides and hormones such as leptin, adiponectin, resistin, 
retinol-binding protein 4 (RBP4), and lipocalin 2 [6-9]. These adipokines have been 
demonstrated to be important regulators of insulin sensitivity and energy metabolism. 
1.2 Brown adipose tissue (BAT)
In contrast to WAT, brown adipose tissue (BAT) is the major depot for 
thermogenesis and energy expenditure [10]. Previously, BAT in human was believed to 
present at interscapular region only in infants and gradually disappear with age. In recent 
years, active BAT has been identified in the cervical, supraclavicular, axillary, and 
paravertebral regions in adult humans by 18F-FDG-positron emission 
tomography/computed tomography (PET/CT) scanning [11, 12]. This finding strongly 
4reinforces our interest in the role of BAT in thermogenesis and energy expenditure in 
human obesity.
It’s been well known that uncoupling protein-1 (UCP1) is the key marker of BAT 
that plays a key role in dissipating chemical energy in the form of heat for non-shivering 
thermogenesis. UCP1 protein expression in BAT is increased in response to cold 
stimulation. Sympathetic nervous system (SNS) is the major regulator of UCP1 
expression and BAT activity through activating β-adrenergic receptor (β-AR) signaling 
pathway [13]. β-AR signaling pathway regulates the enzymatic machinery for lipolysis 
and fuel utilization. The β-adrenergic signaling pathway activates two downstream 
targets, cAMP-dependent protein kinase (PKA) and mitogen-activated protein kinase 
(MAPK) pathways; both pathways regulate UCP1 expression and lipolysis [14]. In brown 
adipocytes, the activation of these kinase pathways controls the transcription of 
peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) which regulates 
mitochondrial biogenesis and UCP1 expression. In addition, there are many other 
molecules and transcription factors involved in the regulation of brown adipocyte 
differentiation and thermogenesis, including PRD1-BF1-RIZ1 homologous domain-
containing 16 (PRDM16), CCAAT/enhancer-binding protein beta (C/EBP-β) and bone 
morphogenetic protein 7 (BMP7) [13].
The heat production in brown adipose tissue results from both lipid and 
glucose/pyruvate combustions. Therefore, the activation of BAT theoretically causes a 
negative energy balance, which could be an attractive therapeutic approach for obesity 
and metabolic syndrome. In previous studies the activation of BAT has been shown to 
5prevent weight gain in mice. In addition, BAT activity was also found to be negatively 
correlated with BMI and body fat percentage in humans [15]. Beyond the classical 
thermogenesis in response to cold, it has been suggested that UCP1-mediated heat 
production is also involved in diet-induced thermogenesis, playing a role in preventing 
the development of obesity. In the 1970s, Rothwell and Stock observed that rats fed a 
cafeteria diet (high in fats and sugars) gained less body weight than expected based on 
caloric intake, and they proposed that excess calories were being burned off by the 
induction of BAT thermogenesis [16]. Indeed, a number of studies proved there was an 
increased Ucp1 mRNA and protein expression in brown adipose tissue of mice and rats
after a high-fat diet (HFD) feeding [17]. Other studies using UCP1-ablated mouse models 
demonstrated that diet-induced thermogenesis is dependent on brown adipose tissue 
activity. In the absence of thermogenic activation of brown adipose tissue, mice develop 
obesity spontaneously [18]. 
Intriguingly, findings from recent investigations demonstrated another type of 
thermogenic adipocyte, brown-like adipocytes (beige adipocytes) that can be recruited in 
WAT, particularly in subcutaneous (SC) WAT [19, 20]. This process is often referred to 
as browning of white adipose tissue. Beige adipocytes share many biochemical 
characteristics with classical brown adipocytes, including enriched mitochondria, 
multilocular lipid droplets and expression of UCP1. However, they originate from 
distinct cellular lineages and express some unique cell markers, such as Cd137, Tbx1, 
Tmed26 and Cited1 [20-22]. 
6Studies have been performed to compare the gene expression profile in BAT 
between human and rodents. The results showed that the interscapular BAT of human 
infants is composed of adipocytes expressing a gene signature of classical brown 
adipocytes [21], while UCP1-positive adipocytes from adult human BAT possess 
molecular signatures that are similar to murine beige adipocytes, rather than classical 
brown adipocytes [20, 21], suggesting that BAT in adult humans may not be classical 
brown adipocytes, but results from the browning of WAT. In animal studies, it has been 
demonstrated that chronic cold exposure, exercise, and endocrine hormones (BMP4&7, 
FGF21and VEGF) can induce the development of beige adipocytes, and this browning 
process is sufficient to alter energy expenditure and glucose homeostasis [23]. Similar 
results have been observed in adult humans; cold-induced BAT activation in human 
adults increases energy expenditure by 10% to 27%, or 150 to 300 kcal a day [24-26]. As 
a consequence of cold exposure, the whole-body glucose disposal, plasma glucose 
oxidation, and insulin sensitivity were improved [24].
1.3 Regulation of adipogenesis
In adipose tissue, mature adipocytes die constantly and are replaced by new 
adipocytes in order to maintain adequate lipid storage capacity. In humans, roughly 10%
of adipocytes are turned over every year, whereas in mice, 0.6% of adipocytes are 
renewed each day [27, 28]. Adipogenesis refers as to the process where adipocyte 
progenitors are differentiated into mature adipocytes. Adipogenesis can be briefly divided
into two phases: determination and terminal differentiation [29]. During the 
7determination phase, mesenchymal stem cells are committed to the adipose lineage and 
become preadipocytes in response to appropriate adipogenic stimulation. Terminal 
differentiation, on the other hand, describes the process by which preadipocytes acquire 
the characteristics of the mature adipocytes [29]. 3T3-L1 cell line has been commonly 
employed as a cellular model to study adipogenesis. Since 3T3-L1 cell line has already 
been committed to the adipocyte lineage, most of the knowledge acquired from studies 
using 3T3-L1 cells is on the regulation of the terminal differentiation process. However, 
little is known about the regulation of determination of adipogenesis, particularly in vivo.
Loss- and gain-of function studies on the terminal differentiation of adipocytes 
revealed that PPARγ is the “master regulator” of fat cell formation, as it is both necessary 
and sufficient for adipogenesis. First, it has been known that mutations of PPARγ in 
human adipocytes showed severe lipodystrophy [30]. Second, in the gain of function 
studies, overexpressing PPARγ in non-adipogenic fibroblasts and myoblasts is able to 
induce these cells to differentiate into mature adipocytes [31, 32]. The C/EBP family 
members are also important transcription factors controlling adipogenesis. C/EBPβ and δ 
act during the early stage of adipocyte differentiation on the induction of the expression 
of PPARγ and C/EBPα. Finally, a positive feedback loop between PPARγ and C/EBPα
promotes the expression of adipogenic genes and stimulates lipid accumulation [33, 34].
There has been recent progress in identifying transcription factors involved in 
adipose determination. BMP4 is secreted by differentiated adipose cells [35] and can, in a 
paracrine fashion, target uncommitted precursor cells in adipose tissue, leading to their 
adipogenic commitment. Additionally, Zfp423 has been identified as a transcriptional 
8determinant for the embryonic fibroblast commitment to the adipose lineage [36]. Zfp423 
has been shown to induce adipose lineage commitment by amplifying the effects of 
BMPs via binding a SMAD-interaction domain. 
Soon after the discovery of the browning process in white adipose tissue, certain
signaling pathways that regulate the browning of WAT have been unveiled. Some novel 
cytokines, including irisin, FGF21, BMPs and meterorin-like protein as well as the 
classic β-adrenergic stimulation have been determined as important inducers of beige 
adipocyte development [37-40]. These factors upregulate the expression of multiple 
transcription factors, co-activators, and other molecular regulators, including PRDM16, 
PGC1α, CIDEA and c/EBPβ [41-43], and positively regulate the browning of WAT. 
2. Adipose tissue dysfunction in obesity and insulin resistance
Insulin is a major regulator of energy metabolism, with a wide range of actions, 
including enhancing glucose uptake and triglyceride synthesis, inhibiting lipolysis in 
adipocytes, and suppressing hepatic gluconeogenesis and glycogenolysis, all of which 
tend to reduce blood glucose and lipid levels. 
The molecular pathway that mediates insulin stimulated glucose uptake has been 
well studied. When insulin binds to the insulin receptor on the cell membrane, the insulin 
receptor is autophosphorylated at its tyrosine residues leading to the activation of its 
tyrosine kinase activity [44]. The insulin receptor then phosphorylates tyrosine residues 
on the insulin receptor substrates (IRSs), which then serve as docking sites for SH2-
9containing enzymes such as PI-3 kinase. This leads to linear signaling cascades that result 
in Akt activation. As the consequence of Akt activation, GLUT4 translocation and 
glucose uptake into skeletal muscle and adipose tissue are enhanced; glycogen synthesis 
in the liver is stimulated [44]. Thus, insulin signaling plays an important role in 
metabolism in multiple insulin responsive tissues. 
Insulin resistance (IR) is the major cause of type 2 diabetes. The mechanisms of 
insulin resistance have been studied intensively for decides. Currently, it’s well accepted 
that insulin resistance is closely related with energy imbalance and obesity. Many 
molecular mechanisms are proposed, including ER stress, oxidative stress, dysregulation 
of lipid homeostasis (including FFA homeostasis), mitochondrial dysfunction, hypoxia 
and others [45]. Among these proposed mechanisms,, the inflammation theory is most 
extensively studied and widely accepted. It well explains the initial local pathology in 
adipose tissue and the following systemic metabolic dysregulation in insulin resistance. 
Some details are described in the following sections.
2.1 Inflammation links obesity and insulin resistance
The role of inflammation in the pathogenesis of obesity-associated metabolic 
disorders was first recognized by a remarkable finding in 1870s showing that the 
nonsteroidal anti-inflammatory drug sodium salicylate improved glycosuria in T2DM 
patients [46]. After decades of research, several general processes in obesity-induced
adipose tissue inflammation have been established including: a) the adipocyte expansion
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and dysfunction, b) the infiltration and activation of immune cells, and c) the 
development of insulin resistance. Details are provided below:
a. Adipocyte expansion and dysfunction:
White adipocyte is the major cell type that stores excess energy derived from food 
[5]. Dietary energy from glucose and lipids are stored mostly in a single large lipid 
droplet in the form of triglyceride in white adipocytes. Therefore, excessive intake of 
macronutrients leads to increased storage of energy in lipid droplets of adipocytes, 
thereby increasing lipid droplet/adipocyte size and promoting adipose tissue expansion. 
The enlarged adipocytes lose their normal function and have an altered secretory pattern 
with a decrease in the secretion of anti-inflammatory adipokines such as adiponectin and 
an increase in the secretion of pro-inflammatory adipokines/cytokines and chemokines 
such as leptin, resistin, tumor necrosis factor alpha (TNFα), interleukin (IL)-6, and MCP-
1. These secretory proteins induce the infiltration and accumulation of immune cells and 
inflammation in the adipose tissue [47, 48].
In addition, adipocyte hypertrophy creates a local hypoxic state, which induces 
the secretion of HIF1, pro-inflammatory cytokines and chemokines and causes M1 
macrophage infiltration and adipose tissue remodeling. Hypoxia also leads to 
overproduction of extracellular matrix components in obese adipose tissue [49], which in 
turn cause adipose tissue fibrosis.
b.  Immune cell infiltration and activation:
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Almost all different types of immune cells have been found to reside in adipose 
tissue, including macrophage, neutrophils, eosinophils, dendritic cells, and T and B 
lymphocytes. In obesity, more immune cells are recruited into white adipose tissue and 
they are switched to pro-inflammatory state, leading to the development of chronic low-
grade inflammation in adipose tissue. Among infiltrated immune cells, macrophages have 
been well accepted to play a key role in chronic adipose tissue inflammation. 
The dominant macrophages residing in healthy adipose tissue are M2 
macrophages, which have an anti-inflammatory role. During obesity, chemokines and 
cytokines from adipocytes recruit monocytes into adipose tissue [50]. In addition, 
hypertrophic adipocytes die at some point. This attracts a vast number of macrophages
into adipose tissue to clear the dead cells, forming the “crown-like structure” in 
hypertrophic adipose tissue [51]. The infiltrated macrophages are differentiated to M1 
macrophages, which are considered as pro-inflammatory macrophages and become the 
major source of substantial amount of pro-inflammatory cytokines, such as TNFα and IL-
6 [50]. Previous studies have shown that the majority of pro-inflammatory cytokines in 
obesity are produced by macrophages [52, 53]. These cytokines recruit other immune 
cells into adipose tissue and induce the phenotypic switch of these cells.
Besides macrophages, recent studies have demonstrated that other types of 
immune cells also contribute to the development of inflammation and insulin resistance 
in adipose tissue. Neutrophils are considered as one of the first immune cells that migrate 
into adipose tissue during obesity, since their numbers are increased within the first week 
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of high fat diet feeding [54]. Neutrophils secrete cytokines to recruit the second wave of 
immune cells, such as macrophages. 
Eosinophils produce many anti-inflammatory cytokines (such as IL-4, IL-10, IL-
13 and TGF-β) and their numbers in adipose tissue are decreased in obesity. Under the 
normal chow-diet condition, ~90% of IL-4-producing immune cells in adipose tissue are 
eosinophils [55]. Disruption of IL-4 signaling pathway by knocking out Stat6 increases 
insulin resistance in mice [56, 57]. 
Immune cells that are involved in adaptive immune responses such as T cells and 
B cells are also found to be altered in number in adipose tissue during obesity and play an 
important role in insulin resistance. Multiple studies reveal that pro-inflammatory cells 
including Th1 CD4 T cells, CD8 T cells and B cells were increased, while anti-
inflammatory cells such as regulatory CD4 T cells (Tregs) and Th2 CD4 T cells were 
decreased in adipose tissue in obesity [58-60]. These obesity-inflamed immune cells play 
a role in initiating the secondary wave of cytokine production by recruiting and activating 
other types of immune cells such as macrophages.
c. The development of insulin resistance:
Infiltrated immune cells in expanded white adipose tissue further deteriorate the 
secretory function of adipose tissue, leading to the increased secretion of cytokines, such 
as TNFα, IL-1, RBP4 and interferon-γ [61, 62]. These cytokines could impair the insulin 
signaling pathway in adipocytes. TNFα is the first identified cytokine that could induce 
insulin resistance. In 1993, Hotamisligil et al. demonstrated that TNFα level was 
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increased in obese adipose tissue (AT) and that TNFα could directly induce insulin 
resistance in adipocytes [63]. Now, many other pro-inflammatory cytokines have been 
demonstrated to have similar effects. We will use TNFα as an example to explain the 
detailed mechanisms of cytokine-induced insulin resistance in section 2.2. 
In addition, these pro-inflammatory cytokines were found to increase adipocyte 
lipolysis and induce adipose tissue fibrosis, which reduce the lipid-storing capacity in 
adipose tissue [49, 64]. Thus, excessive lipids converted from surplus energy are forced 
to deposit in non-adipose tissue such as liver, muscle and pancreas, which leads to 
systemic lipotoxicity and insulin resistance.
2.2 TNFα as a major regulator of adipocyte metabolism and insulin resistance
As mentioned above, TNFα is one of the most important key modulators of 
adipocyte metabolism, with a direct role in several insulin-mediated processes, including 
glucose homeostasis and lipid metabolism [65]. The TNFα levels are increased in obese 
adipose tissue [66]. TNFα is well known to induce insulin resistance by attenuating 
insulin signaling and inhibiting adipogenesis, thereby compromising metabolic functions 
of adipocytes. For instance, TNFα attenuates insulin-stimulated glucose and lipid uptake, 
decreases oxidation of glucose and lipid, increases lipolysis and de novo fatty acid 
synthesis, and inhibits free fatty acids (FFA) esterification to triglyceride. All these 
changes lead to increased fatty acid output from adipocytes, causing the elevation of 
circulating FFAs and systemic insulin resistance. Blocking TNFα using TNFα 
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neutralizing antibody or TNFα deficiency protects mice from high-fat diet-induced 
insulin resistance [63, 67], suggesting that TNFα plays a key role in linking inflammation 
to insulin resistance.
a. TNFα pathway
TNFα mediates its biological effects in adipose tissue via two distinct cell surface 
receptors: tumor necrosis factor alpha receptor 1 (TNFR1) and tumor necrosis factor-
alpha receptor 2 (TNFR2) [68]. TNFR1-induced signals are required and sufficient for 
TNFα-induced insulin resistance [69, 70]. The binding of TNFα to TNFR1 leads to the 
recruitment of several adapter complexes to the trimetric death domain of TNFR1 
(TNFR1-DD). As a consequence, two major downstream pathways are activated. One is
the nuclear factor-kappa B (NF-κB) pathway (by activating IKK-β, which degrades I-κB) 
[71]. The other pathway is the mitogen-activated protein kinase (MAPK) cascades, 
including extracellular signal-regulated protein kinase (ERK), p38 MAPK and c-Jun N-
terminal kinase (JNK) [72, 73]. In addition, several other signaling pathways are 
activated by TNFR1 and TNFR1-DD, such as protein kinase A (PKA), CREB, protein 
kinase C (PKC), PI3K and calcium release [68]. 
TNFα affects adipocyte metabolic function at multiple levels. One of the 
mechanisms that mediate TNFα effect is through inhibiting PPARγ. PPARγ is a master 
regulator of adipogenesis and lipid metabolism. By activating NF-κB, JNK and ERK 
activity, TNFα inhibits PPARγ transcription and activity [74-76]. The inhibition of 
PPARγ in turn suppresses C/EBPα, insulin receptor (IR), insulin receptor substrate-1 
(IRS-1) and GLUT4 expression [77, 78], which are required for insulin-stimulated 
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glucose uptake in adipocytes. In addition, by activating inhibitor κB kinase-β (IKK-β), 
TNFα induces serine phosphorylation of IRS-1, which inhibits insulin-stimulated tyrosine 
phosphorylation of the IR and IRS-1 [79, 80]. 
b. Regulation of lipid metabolism in adipocytes by TNFα
TNFα inhibits insulin action on glucose uptake and oxidation, FFA uptake and 
lipogenesis, and inhibition of FFA release via lipolysis by regulating the above 
mentioned signaling pathways. Moreover, TNFα impairs the lipid storage capacity of 
adipose tissue by suppressing the recruitment and differentiation of new adipocytes from 
precursor cells by inhibiting the induction of PPARγ and C/EBPα expression [81]. In this 
way, TNFα action leads to the development of dyslipidemia, which contributes to 
systemic metabolic complications.
TNFα also regulates the production and secretion of cytokines and adipokines 
from adipose tissue. By regulating the production of other pro-inflammatory cytokines 
(e.g. IL-6 and IL-1), TNFα further amplifies its effects on peripheral tissues. Adiponectin 
enhances insulin sensitivity and improves the serum lipid profile through activating 
AMPK and increasing fatty acid oxidation in muscle [82]. The production of adiponectin 
is suppressed by TNFα as a result of the suppression of PPARγ and C/EBPβ and/or JNK 
activation [83-85], contributing to the mechanism for TNFα-induced dyslipidemia and 
systemic insulin resistance.
Consistent with the inhibition of fatty acid oxidation, TNFα treatment in 
adipocytes also leads to morphological changes in the mitochondrion, together with 
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downregulating the expression of genes that encode components of complex I-V in the 
electron transport chain [86]. The mitochondrial dysfunction by TNFα is reflected by 
decreased mitochondrial membrane potential and reduced production of intracellular 
ATP as well as accumulation of significant amounts of reactive oxygen species (ROS) 
[87]. Additionally, oxidative stress may in turn promote increased production of TNFα 
under adverse metabolic conditions [88].
c. TNFα in BAT thermogenesis
The previously mentioned metabolic changes in WAT led by TNFα are the 
potential mechanisms contributing to insulin resistance. Contradictorily, TNFα seems to 
increase BAT thermogenesis, which is similar to the effect of HFD in BAT. This TNFα-
induced thermogenesis in BAT could be the mechanisms by which body prevents 
excessive weight gain and obesity. Indeed, a similar effect that TNFα increases energy 
expenditure has been reported in cancer cachexia [89]. More specifically, mice receiving 
a single intravenous injection of TNFα resulted in significant, but transient (24-48 hours) 
reductions in food intake and body weight, and increases in rectal temperature, resting 
oxygen consumption (VO2) and brown adipose tissue (BAT) thermogenic activity [90]. 
Similar effect of TNFα was reported in another study, including elevated rectal 
temperature by 0.7 degree as well as increased serum leptin in response to TNFα 
injection [91]. In addition, BAT UCP1 mRNA expression was increased by 1.2-fold 6-
hour after the TNFα treatment, but decreased by 0.8-fold 16-hour after the treatment. The 
levels of UCP2 mRNA expression were also increased in BAT, WAT, and muscle 16-
hour after TNFα treatment [91]. In a third study, a significant increase in UCP2 (242%) 
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and UCP3 (113%) gene expression was observed in skeletal muscle of mice with TNFα 
injection [92].
However, contradictory results were reported in other studies focusing on the 
chronic effects. Brown adipocytes treated with TNFα for 48hour showed a slight 
reduction in UCP1 expression [93]. TNFR1 KO mice fed a HFD had higher UCP1 
expression in BAT, indicating the TNFα reduces UCP1 expression [94]. In addition, a 
chronic TNFα elevation has more complicated impact, and it may compromise BAT 
thermogenesis by promoting BAT atrophy or by impairing BAT differentiation [95]. 
Therefore, it’s likely that the effect of TNFα on BAT thermogenesis may depend on its 
dose and duration.
In the mechanistic studies, TNFα has been shown to activate several different 
signaling pathways such as extracellular-regulated kinases (ERKs), JNKs, p38 MAPKs or 
NF-κB [93]. Some of the pathways such as p38MAPK upregulates BAT thermogenesis, 
while ERK and NF-κB pathways downregulate BAT thermogenesis. Studies with kinase 
inhibitors showed that the inhibition of p38 MAPK significantly reduced the UCP1 
expression in brown adipocytes treated with TNFα, whereas the inhibition of ERK 
showed an opposite consequence. Thus, it’s likely that the overall effect of TNFα on 
BAT thermogenesis depends on the balance of all the pathways that are involved in the 
regulation of UCP1 expression and thermogenesis. 
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2.3 Endotoxin (LPS) in obesity
In addition to the hypertrophic adipose tissue oriented inflammation, recent 
studies have discovered that the alteration of gut microbiota population is a new 
mechanism that connects high fat diet and insulin resistance. Studies have demonstrated 
that high fat diet (HFD) increased the proportion of lipopolysaccharide (LPS) containing 
microbiota in the gut and increased intestinal permeability, which allows LPS to get into 
circulation. As a consequence, the plasma levels of LPS are mildly increased, which is 
hypothesized to mediate HFD-induced metabolic disturbance [96, 97]. Emerging 
evidence has indicated that LPS binds to the toll-like receptor (TLR) 2, 4 and has a 
profound impact on white adipose tissue biology, including inducing inflammation, 
disrupting lipid metabolism and promoting insulin resistance [98-100].
The two main downstream pathways of TLR2/4 have been well studied in 
immune cells, and some studies have shown the similar regulation in mature adipocytes
[101]. First, the activation of TLR2 and 4 turns on the TIRAP/MyD88 dependent 
pathway. This triggers a signaling cascade and ultimately activates of IKKβ and MAPKs 
such as p38 MAPK and extracellular signal-regulated kinase (ERK) 1/2. These kinases in 
turn activate the transcription factor NF-κB and the production of pro-inflammatory 
cytokines and chemokines such as TNFα and IL-6. In another MyD88-independent 
pathway, TLR4 can activate TRAM/TRIF. These adaptors in turn activate interferon 
regulatory factor-3 (IRF3), which induces type I interferon (IFN) expression and involves 
the late phase of NF-κB activation [102]. 
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The mechanisms of LPS to induce insulin resistance in adipose tissue have been 
intensively studied in several models, such as 3T3-L1 cells and primary human/mouse 
adipocytes. Beyond the production and secretion of pro-inflammatory cytokines, the 
activation of TLRs in adipocytes can impair insulin signaling via activating MAPK,
which stimulates serine phosphorylation of insulin receptor substrate 1 [103]. In addition, 
the activation of TLRs induces lipolysis, which leads to dyslipidemia and systemic 
insulin resistance [99]. Moreover, several studies have demonstrated that LPS impairs 
adipogenesis. For example, the exposure to LPS during adipocyte differentiation led to 
the inhibition of adipocyte differentiation of 3T3-L1 cells and human progenitor cells
[104, 105]. This effect of LPS further decreases lipid storage capacity in adipose tissue, 
contributing to the development of dyslipidemia in HFD-induced obesity.   
2.4 Inflammation inhibits the browning of white adipose tissue
Different from the above-mentioned contradictory role of inflammation in BAT 
thermogenesis, quite a few of studies demonstrated that blocking inflammation promotes 
the browning of white adipose tissue in various rodent models. Studies with group 2 
innate lymphoid cells [106], administration of type 2 cytokines IL-4 [57], overexpression 
of VEGF [107], and knockdown of RIP140 in macrophage [108] have suggested that 
reducing pro-inflammatory M1 macrophage polarization or alternatively increasing M2 
macrophage activation could be an important approach to induce the browning of adipose 
tissue. Additionally, amelioration of adipose tissue inflammation by other means, such as 
genetic inhibition of serotonin synthesis in adipose tissue [109], suppression of interferon 
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signaling [110] and knockout of response gene to complement 32 [111] all could induce 
the browning of adipose tissue. In most of these studies, corresponding improvement of 
mitochondrial activity, increase of energy expenditure and reduced weight gain were 
observed under the high fat diet condition, which ultimately led to the improvement of 
insulin sensitivity.
3. Mitochondrial function and insulin sensitivity  
As mentioned previously, fatty acid is not toxic when stores in lipid droplets as 
triglyceride. However, as a consequence of positive energy balance, substantial amount 
of lipids come to adipose tissue and adipocytes expand to store them. When adipocyte 
expansion reaches its limited capacity, lipolysis will be elevated and fatty acids will be 
released into circulation, which leads to lipotoxicity and insulin resistance. Since fatty
acid is primarily a form of energy, the elevation of fatty acid oxidation in mitochondrion 
and energy expenditure is theoretically beneficial to insulin resistance. This notion has 
been proved by studies looking at the “browning” of WAT, which is speculated to 
substantially increase energy oxidation in adipose tissue. Since the mitochondrial 
function in adipocytes has been valued critical in regulating energy balance and insulin 
sensitivity, I summarize the biology and pathology of mitochondrion in adipocyte.
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3.1 Mitochondrial function in oxidative metabolism
Mitochondrion plays a key role in energy metabolism as a “powerhouse unit” of 
the cell.  Many key metabolic reactions take place in mitochondrion such as pyruvate 
oxidation, fatty acid β-oxidation, the tricarboxylic acid (TCA) cycle, and oxidative 
phosphorylation (OXPHOS) [112]. 
Eukaryotic cells have the ability to alter mitochondrial biogenesis. In order to 
adapt energy demands during growth or stress, cells change the morphology or remodel 
the organization and distribution of mitochondria [113]. PGC1α plays a central role in the 
regulation of mitochondrial biogenesis and oxidative function. The expression of PGC1α 
is regulated by the nutrition status; increased NAD+/NADH and AMP/ATP ratios 
activate PGC1a via SIRT1-mediated deacetylation and/or AMPK-mediated 
phosphorylation, respectively[114, 115]. PGC1α regulates the activation of multiple 
transcriptional factors including the nuclear respiratory factors, NRF-1 and NRF-2, and
members of the nuclear receptor (NR) superfamily such as the peroxisome proliferator-
activated receptor α (PPARα) and estrogen-related receptors or ERRs (ERRα, ERRβ, and 
ERRγ). Activation of these transcription factors is critical for the control of mitochondrial 
biogenesis and oxidative metabolism including fatty acid β-oxidation, the TCA cycle, 
mtDNA replication and OXPHOS [116]. In addition, SIRT3 has been shown to activate 
PGC-1α, which is required for the induction of several components of the ROS-
detoxifying machinery [117]. 
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3.2 Mitochondrial dysfunction and insulin resistance
Mitochondrial deficiency has been linked to the major classes of age-related 
disease, including diabetes, neurodegenerative disease, cardiac disease, and cancer [118-
120]. The impaired mitochondrial function has been found in muscle, liver, adipose 
tissue, and beta cell in insulin resistant individuals, which is indicated by reduced insulin-
stimulated glucose uptake and/or metabolism as well as reduced mitochondrial OXPHOS 
activity [121].
In adipocytes, normal mitochondrial function has been proved to be critical for 
the regulation of insulin sensitivity. Mitochondrial dysfunction is closely associated with 
insulin resistance. Although HFD could temporarily increase mitochondrial number and 
activity due to a prompt adaptive response, a chronic increase in fuel influx can induce 
overproduction of reactive oxygen species (ROS) and mitochondrial damage [122, 123]. 
Downregulation of PGC1α in caloric excess state could be the main cause of oxidative 
stress resulting from mitochondrial dysfunction and ROS overproduction. The 
dysfunctional mitochondria lead to the profound changes in adipocyte metabolism and 
function, including the inhibition of pre-adipocyte differentiation, increased lipid 
peroxidation, decreased fatty acid β-oxidation and decreased OXPHOS activity. All of 
these changes contribute to the development of insulin resistance [124]. 
3.3 Reactive oxygen species (ROS) 
Mitochondrial electron transport chain (ETC) delivers electron pairs to molecular 
oxygen, the terminal acceptor, to form H2O. In this process, molecular oxygen 
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occasionally becomes partially reduced by a single electron at complexes I and III, and 
forms superoxide anion (O2∙-), which belongs to the toxic reactive oxygen species (ROS). 
Moderate generation of ROS in adipocytes during insulin stimulation enhances insulin 
sensitivity via stimulating insulin receptor autophosphorylation and PTEN oxidation, 
leading to the activation of downstream signaling events through the PI3K/Akt cascade 
[125, 126]. However, under the condition of overnutrition, the long-term exposure to high 
levels of ROS alters mitochondrial function, thereby causing insulin resistance.
There are two theories regarding how ROS induces insulin resistance. One theory 
explains that accumulation of ROS leads to nonspecific oxidative damage to 
mitochondria. The other is that mitochondrial ROS are part of a redox signaling pathway 
that modulates the balance between energy utilization and storage [127]. Disruption of 
these redox signals by chronic overnutrition and lack of ATP demand contribute to the 
development of metabolic syndrome phenotype. Since the levels of oxidative damage to 
mitochondria and the changes in the specific activity of components of mitochondrial 
ETC complexes tend to be relatively modest at least at the beginning state of metabolic 
syndrome [128], the second theory seems to be more favorable for explaining the 
initiation of metabolic dysregulation. 
Within the redox signaling pathway, aconitase in TCA cycle is particularly 
sensitive to superoxide since this enzyme has an iron–sulfur center in its active site. 
Superoxide inactivates aconitase, leading to the accumulation of citrate in the matrix, 
which can be exported to cytoplasm for fatty acid synthesis [129]. Therefore, ROS leads 
to the diversion of acetyl-CoA away from oxidative phosphorylation and towards 
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lipogenesis. Another form of ROS is hydrogen peroxide, which can be converted from 
superoxide by superoxide dismutase. Hydrogen peroxide easily diffuses from the 
mitochondrial matrix to the cytosol, and thereby acts as a signal to the rest of the cell 
[130]. It inhibits pyruvate dehydrogenase kinase 2 (PDHK2), which in turn activates 
pyruvate dehydrogenase complex (PDC), facilitating the movement of carbohydrate to 
acetyl-CoA and into the TCA cycle. Coupled with the inactivation of aconitase by 
superoxide, these signals enable mitochondria to respond to overnutrition by slowing 
down the TCA cycle and fatty acids oxidation, while simultaneously increasing the 
breakdown of carbohydrates for lipogenesis. In addition, hydrogen peroxide acts to 
modify the function of protein involved in the breakdown of fatty acids [127]. Defects in 
mitochondrial fatty acid oxidation increase intracellular fatty acid intermediate 
metabolites (fatty-acyl-CoA and diacylglyerol), which activate stress-sensitive kinases 
such as PKC, IKK and JNK and in turn disrupt insulin signaling. 
Moreover, insulin signal regulates mitochondrial DNA and protein synthesis, and 
potently stimulates mitochondrial oxidative capacity and ATP production. Therefore, the 
impaired insulin signaling pathway in the insulin resistant state further deregulates 
mitochondrial biogenesis and function. 
In summary, positive energy balance is believed to be the fundamental cause of 
obesity and adipose tissue expansion; inflammation in hypertrophic adipose tissue is a 
critical inducer of adipose tissue dysfunction, which ultimately leads to systemic insulin 
resistance and type 2 diabetes. Elevation of LPS induced by high fat diet is a recently 
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identified mechanism of adipose tissue inflammation. Therefore, it’s of interest to expand 
our understanding of LPS effect on adipocytes and to identify new molecular players that 
involve in this signaling pathway. In the meantime, exploring effective nutritional 
strategy to regulate energy metabolism and prevent insulin resistance is equally important. 
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CHAPTER 2
EFFECT OF LIPOPOLYSACCHARIDES ON ADIPOGENIC 
POTENTIAL AND PRE-MATURE SENESCENCE OF
ADIPOCYTE PROGENITORS
The chapter is modified from the manuscript:
Ming Zhao and Xiaoli Chen. Effect of lipopolysaccharides on adipogenic potential and 
pre-mature senescence of adipocyte progenitors. American Journal of Physiology: 
Endocrinology and Metabolism. Under review (2nd minor revision).
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SUMMARY
The elevation of circulating LPS has been associated with obesity and aging. 
However, whether and how LPS contributes to adipose tissue dysfunction is unclear. In 
this study, we investigated the effect of LPS on the adipogenic capacity and cellular 
senescence of adipocyte progenitors. Stromal-vascular cells were isolated from inguinal 
adipose tissue of C57BL/6 mice and treated with LPS during the different time periods of 
adipocyte differentiation. We found that LPS treatment for 24hr prior to the induction of 
differentiation led to the most profound effect on the inhibition of adipogenesis, as 
evidenced by the morphological changes and the decreased mRNA expression of 
adipocyte marker genes. In addition, LPS induced features of pre-mature senescence of 
SV cells, including the activation of p53, the elevation of SA-β-gal activity and increased 
hydrogen peroxide production, but not telomere length. Upon LPS treatment, SV cells 
also developed senescence-associated secretory phenotype (SASP), as demonstrated by 
the increased expression of TNFα, IL-1β, IL-6, MCP1 and VEGFα.  Blocking LPS-
induced NF-κB activation and cytokine production by Bay 11-7082 failed to rescue the 
impaired adipogenesis and the reduction in PPARγ and Zfp423 expression. On the 
contrary, Rosiglitazone had little effect on cytokine production, but corrected the 
defective adipogenic potential. In conclusion, we demonstrate that LPS inhibits
adipogenesis by disrupting the differentiation of adipocyte progenitors in a NF-κB-
independent manner; LPS also induces pre-mature senescence of adipocyte progenitors.
Our data suggest that LPS could be a potential contributor to the defective adipogenesis 
and the development of cellular senescence in adipose tissue during obesity and aging. 
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INTRODUCTION
The main functions of white adipose tissue (WAT) are to store lipids and secrete 
metabolic regulators of adipokines and cytokines. Dysfunctional adipose tissue, 
characterized by reduced adipogenesis and increased cellular senescence and 
inflammation, commonly associates with obesity and aging [131]. Adipose tissue 
dysfunction impairs lipid storage and dysregulates production of adipokines and 
cytokines, leading to metabolic derangement, adipose tissue inflammation, insulin 
resistance, and type 2 diabetes [132-135]. 
Adipogenesis relies on the formation of new adipocytes from adipocyte 
progenitor cells. Adequate adipogenesis capacity is essential to sequester lipids in adipose 
tissue, which protects against the ectopic fat deposition and the development of insulin 
resistance [136-138]. Adipocyte hyperplasia has been considered as a protective 
mechanism when compared with adipocyte hypertrophy in terms of the metabolic 
consequences of adipose tissue expansion [139]. In diet-induced obesity, adipocyte 
hyperplasia (adipogenesis) is impaired. As a result, adipocyte hypertrophy and insulin 
resistance are developed. Studies in lean and obese subjects have shown that in obese 
adipose tissue, the number of adipocyte progenitor cells is increased by up to 10 fold, 
while the mature adipocyte number is decreased compared to lean adipose tissue [51, 
131]. This observation suggests that there is an imbalance between the formation of new 
adipocytes and the death of mature adipocytes in obese adipose tissue, leading to a 
reduction in lipid buffering capacity in adipose tissue. As a consequence, excessive fatty 
acids are released into the circulation, contributing to the development of ectopic fat 
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accumulation, inflammation, and insulin resistance [140]. Studies also indicate that the 
decreased total adipocyte number remained several months after the removal of high fat 
diet (HFD), indicating that HFD has a long-term impact on the disruption of adipogenesis 
[51]. 
Cellular senescence refers to the irreversible arrest of cell cycle progression [141]
and it can be categorized into two different types, i.e. replicative senescence and stress-
induced senescence. Replicative senescence can occur after a certain number of mitotic 
divisions in aged cells [142], while stress-induced senescence can be induced anytime 
during the exposure of cells to certain stresses [143] such as increased levels of reactive 
oxygen species (ROS), irradiation, and other metabolic signals and inflammatory insults 
[144-147]. Some common features of senescent cells include the activation of p53 and 
p38 MAPK signaling pathways, senescence-associated secretory phenotype (SASP) and 
increased β-galactosidase activity and ROS production [148-151]. Moreover, in 
adipocyte progenitor cells, senescence leads to decreased differentiation capacity and 
altered production of extracellular matrix (ECM) proteases [152, 153]. This cellular 
process is associated with age-related metabolic disorders. In addition, obesity has been 
shown to accelerate the development of cellular senescence in adipose tissue [154].
Adipogenesis can be regulated at the early stages by controlling the intrinsic 
differentiation potential and at the late differentiation stage by regulating the lipid 
accumulation process. It would be of interest to know if HFD impairs the intrinsic 
differentiation potential which may be associated with its long-term effect on 
adipogenesis. It has been well accepted that chronic low-grade inflammation in both 
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obese and aged subjects is an important mediator of adipose tissue dysfunction. Studies 
have demonstrated that high fat diet (HFD) alters intestinal microbial profile and 
increases intestinal permeability, leading to increased production and leaking of 
lipopolysaccharide (LPS) [96]. As a consequence, the plasma levels of LPS are mildly 
increased, which is hypothesized to mediate HFD-induced metabolic disturbance [96, 
97]. In addition, LPS levels were also found to be increased in the circulation in aged 
humans [155]. Emerging evidence has indicated that LPS binds to the Toll-like receptor 4 
and has a profound impact on white adipose tissue biology, including inducing 
inflammation, disrupting lipid metabolism and promoting insulin resistance [98, 99].
With regards to the regulation of adipogenesis, studies from in vitro cultures of 
3T3-L1 cells and human adipocyte progenitor cells consistently demonstrated that LPS 
treatment during adipocyte differentiation led to the inhibition of adipocyte 
differentiation [104, 105]. Previous reports have also shown that LPS induces cellular 
senescence in multiple types of cells [156-158]. However, the effect of LPS on the 
intrinsic adipocyte differentiation potential and senescence of adipose stromal-vascular 
(SV) cells has not been investigated previously. It has been shown that there are fat depot 
differences in the regulation of metabolism, the expression of adipogenic genes such as 
PPARγ, Zfp423, and Pref1, and adipogenic capacity [159-161]. For instance, adipocyte 
progenitor cells derived from inguinal fat depot have better adipogenic potential than 
those from epididymal fat depot [162]. It is possible that LPS may have a differential 
impact on adipogenesis and metabolism in different depots. However, most of previous in 
vitro studies were conducted in 3T3-L1 cells, focusing on the effect of LPS on 
inflammation, lipid metabolism and adipogenesis [104, 105, 163-166]. The effect of LPS 
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on the intrinsic differentiation potential of adipocyte progenitors using primary inguinal 
SV cell cultures which reflect better the physiological conditions has not been previously 
reported. 
In this study, we explored the impact of LPS on the intrinsic adipogenic capacity 
as well as the development of cellular senescence of inguinal SV cells.  Additionally, we 
determined the role of NF-κB signaling pathway in mediating these effects of LPS. We 
found that LPS inhibited the intrinsic adipogenic potential of inguinal SV cells in a NF-
κB-independent manner. Rosiglitazone could block the LPS inhibition of adipogenesis, 
but not LPS-induced inflammation in inguinal SV cells. Moreover, SV cells underwent 
pre-mature senescence in response to LPS treatment.
MATERIALS AND METHODS
Animals
C57BL/6 mice purchased from Jackson Laboratory were housed in specific 
pathogen-free facility at the University of Minnesota. Animal handling followed the U.S. 
National Institutes of Health guidelines, and experimental procedures were approved by 
the University of Minnesota Animal Care and Use Committee. Mice were maintained on 
a 12:12-h light-dark cycle, with food and water available ad libitum.
Cell culture
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Stromal-vascular (SV) cells were isolated from inguinal WAT of male C57BL/6 
mice at 12-14 weeks of age as described previously [167]. Fat pads were minced and 
digested in Krebs-Ringer bicarbonate HEPES (KRBH) buffer (pH 7.4) with collagenase 
(2 mg/ml solution). After a 1-h digestion, SV cells were separated by centrifugation at 
1500 rpm for 10 min and washed twice with KRBH buffer. SV cells were then collected 
and cultured in growth medium (DMEM plus 10% FBS) until confluence. Confluent cells 
were treated with LPS at different doses for 24-hour unless otherwise mentioned in the 
context. After LPS treatment, cells were washed with PBS for 3 times and differentiated 
with a differentiation cocktail (100 IU/ml penicillin-streptomycin, 10% fetal bovine 
serum, 115 μg/ml methylisobutylxanthine, 390ng/ml dexamethasone, and 1 μg/ml 
insulin) for 3 days. In the corresponding experiments, 3µM Bay 11-7082 or 1 µM 
Rosiglitazone was added from 3 hour prior to LPS treatment to day 3 of differentiation. 
The cultures were then continued with DMEM with100 IU/ml penicillin-streptomycin, 
10% fetal bovine serum, and 1 μg/ml insulin for another 4 days. 
Oil-Red O Staining
Differentiated adipocytes were washed twice with PBS and fixed with Baker’s 
Formalin for 30 min at 4°C. Cells were then stained for 10 min in freshly diluted Oil Red 
O solution. Finally, cells were washed with running water and observed under the 
microscope. 
Western blotting analysis
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Proteins were extracted from cell samples using RIPA buffer (Sigma, St. Louis, 
MO, USA) containing protease inhibitors and phosphatase inhibitor cocktail. Equivalent 
amounts of proteins were separated on 10% SDS-PAGE gel and then transferred to 
nitrocellulose membranes. The membranes were probed with PPARγ, C/EBPβ, NF-κB 
p65, phospho-NF-κB p65 (Ser536), P53, phospho-P53 (Ser15), P38 MAPK, phosphor-
P38 MAPK (Thr180/Tyr182) or β-Actin (Cell Signaling, MA, USA) antibodies 
according to the recommendations of the manufacturers. ECL Western Blotting Detection 
System (GE Healthcare BioSciences, Piscataway, NJ, USA) was used to detect antibody 
reactivity. 
Relative quantitative real-time RT-PCR
Total RNA was extracted from cells using the Trizol method (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer's instructions. cDNA was synthesized 
from DNase-treated RNA (3µg) using a Superscript II reverse transcriptase kit 
(Invitrogen, Carlsbad, CA, USA). Real time-PCR was performed using SYBR Green 
qPCR Master Mix (Qiagen, MD, USA) with an ABI Step One Plus real-time PCR 
System (Applied Biosystems, Foster City, CA, USA). Primer sequences are provided in 
Table 1. Results are normalized to TBP using the ΔΔCt method and presented as levels of 
expression relative to that of controls. 
Senescence Associated-β-Galactosidase activity Assay
Senescence associated-β-galactosidase activity was determined by using 
commercially available kit from Thermo Scientific (Rockford, IL, USA). According to 
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the manufacturer’s instruction, a portion of cell lysate was mixed with β-galactosidase 
assay reagent and incubated for 30 minutes at 37 °C. The absorbance was determined at 
405nm in a microplate reader. The readings were then normalized by the protein 
concentration for each sample, as determined by BCA assay. 
Senescence Associated-β-Galactosidase staining
SV cells were seeded in 6-well plates and split when reached 80% confluence.  
SV cells were treated without and with LPS and passaged 4 times. β-galactosidase 
staining was performed using cellular senescence assay kit from EMD Millipore 
(Billerica, MA, USA) according to the manufacturer’s instruction. Briefly, cells were 
fixed with fixing Solution for 10 minutes. After rinsing with PBS, cells were incubated 
with X-Gal solution at 37°C until blue color developed. Cells were then washed with 
PBS and blue stained cells were counted in 10 randomly captured fields per well under 
microscope (100X magnification). 
Hydrogen Peroxide Assay
Hydrogen peroxide level in cell lysate was determined by using Amplex Red 
Hydrogen Peroxide Assay Kit (Invitrogen, Eugene, OR, USA). Briefly, hydrogen 
peroxide produced by the cells was assessed by incubating the cell lysate in a reaction 
mixture containing Amplex Red and then determining the absorbance at 560 nm in a 
microplate reader, as per the manufacturer's instructions. The readings were then 
normalized by the protein concentration of cells for each sample. 
Telomere length measurement
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Telomere length was measured by quantitative PCR, as described previously [168, 
169]. The total DNA was extracted from cultured SV cells. Samples were digested in 
lysis buffer (0.01 M Tris–HCl, 0.25 mM EDTA, 0.5% SDS, pH 8.3) containing 100 
µg/ml proteinase K and extracted with chloroform and 8 M potassium acetate. The 
supernatant was collected and precipitated with isopropyl alcohol and ethanol. Telomere 
length was determined by detecting terminal restriction fragment (TRF) length using real-
time PCR. The value was normalized to the levels of single copy gene 36B4, which 
encodes acidic ribosomal phosphoprotein PO. 
Statistical analysis
Results are expressed as means ± SEM. Differences in the parameters between 
two groups were evaluated using Student's t-test with a 0.05 2-sided significance level. 
One way ANOVA was used to compare the differences between multiple groups. A value 
of P < 0.05 was considered significant.
RESULTS
Short-term exposure of inguinal SV cells to LPS reduces adipocyte differentiation 
First, we examined the effect of exposure to LPS during the different time periods 
of the differentiation process on the inhibition of adipogenesis. Stromal vascular (SV) 
cells were isolated from inguinal fat depot of regular chow diet (RCD)-fed C57/B6 mice 
at 12-14 weeks of age. Cells were treated with 1µg/ml LPS at the different time periods 
as indicated in Fig. 1A, i.e. before the initiation of differentiation (day -1 to day 0), 
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during the early (day 0 to day 3) and late (day 5 to day 7) stage of differentiation. When 
added during day -1 to 0 or day 0-3, LPS significantly inhibited adipocyte differentiation, 
as demonstrated by the changes in morphological differentiation (Fig. 1B) and decreased 
expression of adipogenic (PPARγ, C/EBPα, GLUT4, LPL) and lipogenic (SREBP1c, 
SCD1, FASN) genes (Fig. 1C). However, when added during the late stage (day 5-7) of 
differentiation, LPS did not affect the morphology of differentiated adipocytes (Fig. 1B), 
but caused the down-regulation of mRNA expression of genes involved in lipogenesis 
including PPARγ, GLUT4, LPL, SREBP1c, SCD1, and FASN (Fig. 1C). Surprisingly, 
treatment of SV cells with LPS only for 24h prior to the addition of differentiation 
cocktail (day -1 to 0) led to the most profound effect on the inhibition of adipogenesis, as 
evidenced by the morphological changes (Fig. 1B) and the mRNA expression of 
adipocyte marker genes examined in the cultures on day 7 of differentiation (Fig. 1C). 
Since 24h prior to the induction of differentiation is the crucial period for LPS effect on 
adipocyte differentiation, LPS was only added at this time period in the following 
experiments. Since PPARγ is the master regulator of adipogenesis, we measured its 
expression during differentiation. Fig. 1D shows that the suppression of PPARγ by LPS 
in SV cells persisted during adipocyte differentiation.  
LPS induces pre-mature senescence of adipose SV cells
Cellular senescence of adipocyte progenitors has been associated with decreased 
differentiation capacity. Therefore, it is of interest to examine if LPS induces cellular 
senescence of adipose SV cells. Our results showed that 24h LPS treatment (day -1 to day 
0) significantly induced p53 phosphorylation in SV cells (Fig. 2A). Consistently, LPS 
treatment led to an increase in senescence-associated β-galactosidase activity (Fig. 2B) 
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and β-galactosidase positive cells (Fig. 2C) as well as an upregulation of C/EBPβ protein 
expression in SV cells (Fig. 2A). In addition, the phosphorylation of p38 MAPK and NF-
κB p65 was increased (Fig. 2A), so was H2O2 production in 24h LPS-treated SV cells 
(Fig. 2D). Moreover, LPS-treated SV cells exhibited significant SASP, as demonstrated 
by a marked increase in the mRNA expression of TNFα, IL-1β, IL-6, MCP1 and VEGFα 
when compared with control cells (Fig. 2E). We next determined if LPS-induced 
senescence is telomere-dependent. To evaluate the effect of LPS on telomere length, we 
passaged SV cells 4 times in the presence or absence of LPS and measured telomere 
length every passage. As shown in Fig 3F, telomere length was not changed after 
passaging 3 times in both control and LPS-treated SV cells. After passaging 4 times, 
telomere length was significantly shortened in control and LPS-treated cells compared to 
unpassaged SV cells. However, LPS treatment did not seem to accelerate telomere 
shortening by passaging, suggesting that LPS induces senescence via a telomere-
independent mechanism.   
LPS inhibition of adipogenesis is NF-κB independent
We explored the molecular pathways that possibly mediate LPS inhibition of 
adipogenesis. Inflammation has been known to play a role in regulating adipocyte 
differentiation. We then investigated the role of cellular inflammation in mediating LPS 
inhibition of adipocyte differentiation. First, we determined whether LPS induces 
persistent cellular inflammation which may lead to the inhibition of adipocyte 
differentiation. As shown in Fig. 2A, LPS treatment from day -1 to 0 significantly 
induced the activation of NF-κB p65 in SV cells when examined on day 0. However, the 
activation of NF-κB by LPS was resolved quickly.  One day or 7 days after the removal 
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of LPS, NF-κB p65 phosphorylation was not different anymore between control cells and 
cells with LPS treatment during day -1 to 0 (Fig. 3A). Similar results were perceived with 
the mRNA expression of TNFα, IL-1β and MCP1 (Fig. 3B). Only the expression of IL-6 
on day1 was still significantly higher in LPS-treated cells compared with controls. These 
results suggest that the impact of 24h LPS treatment on inflammatory response is not 
persistent during adipocyte differentiation.
Since NF-κB activation can trigger the downstream pathway that directly inhibits 
PPARγ activity, it is likely that NF-κB mediates the LPS inhibition of early-stage 
preadipocyte differentiation. To test this hypothesis, we blocked NF-κB pathway by Bay 
11-7082 from 3 hours prior to LPS treatment until 3 days after differentiation. Bay 11-
7082 significantly reduced LPS-induced gene expression of cytokines such as TNFα, IL-
1β and IL-6 (Fig. 4A) as well as NF-κB phosphorylation (Fig. 4B), suggesting the 
successful inhibition of NF-κB. However, neither the down-regulation of PPARγ nor the 
inhibition of adipogenesis was reversed by Bay 11-7082 (Fig. 4B and 4C). To determine 
if the NF- κB  activity impacts the long-term effect of LPS on the inhibition of 
adipogenesis, LPS and Bay 11-7082 were added to SV cell cultures during the entire 
period of differentiation process (day-1 to day7). Similar to the short-term effect of LPS, 
Bay 11-7082 was not able to prevent LPS inhibition of adipocyte differentiation (Fig. 4D) 
and adipogenic gene expression (Fig. 4E). These results suggest that LPS effect on the 
early stage of adipogenesis is at least in part independent of NF-κB signaling pathway 
activation. 
39
LPS regulates the expression of preadipocyte differentiation genes in SV cells
Since LPS was removed before the induction of differentiation, the possible 
mechanism for its anti-adipogenic effect could be due to its impairment in the intrinsic 
adipogenic capacity of adipocyte progenitors. We then examined the mRNA expression 
of key factors controlling preadipocyte differentiation including C/EBPδ and Zfp423 and 
preadipocyte marker Pref-1 in SV cells after 24h LPS treatment (day -1 to 0). As shown 
in Fig. 5A, LPS treatment from day -1 to day 0 led to a significant reduction in the 
expression of Zfp423, Pref-1, and PPARγ, but an increase in C/EBPδ expression. As 
previously reported, C/EBPδ has a pro-adipogenic, while Pref-1 an anti-adipogenic role 
[159, 170]. The patterns of C/EBPδ and Pref-1 expression does not match their role in 
adipocyte differentiation, suggesting that they may not be directly involved in LPS 
inhibition of adipogenesis. It seems that the down-regulation of Zfp423 is consistent with 
its regulatory role in adipogenesis as an upstream activator of PPARγ (Fig. 5A). 
Moreover, our results showed that Bay 11-7082 had no effect on LPS-induced reduction 
in Zfp423 expression in SV cells (Fig. 5B). Additionally, we determined if restoring 
PPARγ activity can reverse LPS inhibition of adipogenesis. Rosiglitazone was given 
from 3 hours prior to LPS treatment until 3 days after differentiation. As shown in Fig 
5C, Rosiglitazone completely restored the LPS inhibition of SV cell differentiation 
capacity. Rosiglitazone significantly upregulated PPARγ protein expression in both 
control and LPS-treated cells (Fig. 5D and 5E), without affecting Zfp423 expression (Fig. 
5B). However, Rosiglitazone was not able to suppress the LPS-induced upregulation of 
cytokine gene TNFα and IL-6, but it did significantly inhibit LPS-induced HIF1-α and 
VEGFα expression (Fig. 5E).  
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DISCUSSION
Adequate adipogenesis is essential for sequestering fatty acids in adipose tissue, 
thereby preventing ectopic lipid accumulation and maintaining insulin sensitivity [136-
138]. The recruitment of new adipocytes from adipose precursor cells, a process called 
adipocyte hyperplasia, increases lipid storage capacity and is believed to have a 
beneficial role in metabolic regulation [136-138]. In this study, we investigated the LPS 
regulation of adipogenic potential of adipocyte progenitor cells in primary SV cells 
isolated from mouse inguinal adipose tissue. Compared to 3T3-L1 cells, primary adipose 
SV cells have been known to represent better adipocyte progenitor cells for studying 
adipogenesis. Our results demonstrate that the short-term exposure to LPS prior to the 
initiation of adipocyte differentiation permanently impairs the adipogenic capacity via an 
NF-κB-independent mechanism and induces telomere-independent pre-mature 
senescence in SV cells. These results suggest that the elevation of plasma LPS may 
contribute in part to the impaired adipogenesis and cellular aging of adipocyte progenitor 
cells in obesity and aging. 
Most of previous studies conducted in adipose cell lines have focused on the 
inhibitory effect of inflammation on adipogenesis by examining the effect of adding 
inflammatory factors to the adipocyte cultures either during the entire period of 
differentiation process or the short-term effect on mature adipocytes [104, 171, 172]. The 
present study attempted to more precisely understand the target points where LPS does its 
inhibitory effect on adipocyte differentiation in inguinal SV cell cultures. We therefore 
examined the inhibitory effect of LPS by adding it to the SV cell cultures during various 
time periods of differentiation process. We found that LPS has its most profound 
41
inhibitory effect when added to the SV cells 24h prior to the initiation of differentiation. 
This effect could not be reversed by inhibiting inflammation or blocking NF-κB activity 
as will be discussed further later. Our findings suggest that LPS inhibits adipogenesis via 
blocking the early stage of SV cell differentiation. These findings also suggest that the 
increased levels of endotoxin in obesity and aging could contribute to decreased 
adipogenesis and lipid storage capacity of subcutaneous adipose tissue. When added to 
differentiated adipocytes during day5-7, LPS does not affect adipocyte morphology, but 
disrupts adipocyte lipid metabolism. For instance, LPS significantly inhibits mRNA 
expression of genes involved in lipogenesis such as PPARγ, GLUT4, LPL, SREBP1c, 
FASN and SCD1. PPARγ has two major functions in 1) regulating adipogenesis 
(adipocyte differentiation) and 2) lipid metabolism in mature adipocytes. LPS treatment 
from day -1 to 0 affects adipocyte differentiation, while adding LPS from day 5-7 mostly 
affects PPARγ-mediated lipid metabolism.
Cellular senescence, a process of growth arrest, is a cellular mechanism protecting 
against unrestricted growth of damaged cells [173]. This event can be induced in aged 
subjects and in cultured cells after serial passaging [142]. The above mentioned 
senescence inducers activate p53, p16Ink4a, or both, which in turn induce cell-cycle arrest 
[174]. Telomere shortening, which has been linked with the cellular aging process, is an 
inducer of replicative senescence [175], while stress-induced pre-mature senescence is 
mostly via a telomere-independent mechanism [143]. Studies have shown that 
preadipocytes isolated from aged subjects display cellular senescence, including impaired 
preadipocyte differentiation, increased inflammation, upregulation of C/EBPβ, and 
elevated senescence associated β-gal activity [131]. Moreover, preadipocytes isolated 
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from obese individuals show similar senescent features, indicating that obesity can induce 
the development of cellular senescence in adipose tissue [131]. However, the underlying 
factors that induce cellular senescence in obesity remain unknown. The results from a 
recent study [176] have shown that acute LPS injection induces the gene expression of 
cytokines while reducing adipogenic gene expression in visceral adipose tissue. They 
further demonstrated that the LPS-induced change in adipogenic and cytokine gene 
expression occurs primarily in the SV fraction, suggesting that SV cells could be a 
potential target of the LPS effect on senescence and adipogenesis in vivo. In this study, 
we showed that LPS treatment resulted in an upregulation of P53 phosphorylation and 
C/EBPβ protein expression induced SASP (TNFα, IL-1β, IL-6, MCP1 and VEGFα) and 
increased SA β-galactosidase activity in inguinal SV cells. However, LPS does not seem 
to accelerate telomere shortening induced by passaging cells. These results suggest that 
LPS serves as a potential inducer of telomere-independent pre-mature senescence of 
adipocyte progenitor cells. In addition, LPS stimulated HIF1-α gene expression, which 
has a role in the regulation of adipose tissue fibrosis [177] that commonly develops
during obesity and aging. Thus, our results suggest that the elevation of LPS may also 
contribute to the remodeling of adipose tissue in obesity and aging. Increased C/EBPβ 
expression by LPS seems to be contradictory to its role in adipogenesis. However, it has 
been known that there are two isoforms of C/EBPβ, LAP and LIP. LAP plays a role as a 
stimulator of adipogenesis, while the short isoform, LIP, inhibits adipogenesis [178]. In 
the senescent adipose tissue, both LAP and LIP are increased, but LIP increased more 
significantly, which leads to an overall inhibition of adipogenesis [179]. In addition, 
C/EBPβ is not the only transcription factor that controls adipogenesis. Adipogenesis is 
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regulated by multiple transcription factors including PPARγ, C/EBPα, and C/EBPβ. 
Among them, PPARγ and C/EBPα are known to play key roles in controlling 
adipogenesis. We observed that both PPARγ and C/EBPα were decreased by LPS. Thus, 
we believe that decreased PPARγ and C/EBPα are likely the major contributors to the 
LPS inhibition of adipogenesis.
The inhibitory effects of inflammatory inducers such as LPS, TNFα and 
macrophage-conditioned medium on adipocyte differentiation when they are added 
during the adipocyte differentiation process have been extensively studied [104, 171, 
172]. The mechanism for the effect of proinflammatory factors on adipogenesis is largely 
speculated to be through the direct activation of NF-κB pathway, which in turn reduces 
PPARγ activity during adipocyte differentiation process [104, 171, 172]. Therefore, we 
determined the role of NF-κB signaling pathway in the LPS-induced intrinsic inhibition 
of adipogenesis. We evaluated the dynamic change of NF-κB signaling activation as well 
as the effect of blocking NF-κB activity during adipocyte differentiation after LPS 
treatment. Interestingly, we found that the LPS-induced NF-κB activation and 
inflammatory cytokine production in SV cells was quickly resolved within 24h after the 
removal of LPS from the cultures. However, the 24h exposure to LPS prior to the 
addition of differentiation cocktail (from day -1 to day 0) had a permanent impact on 
adipogenesis and PPARγ expression even after LPS was removed from the cultures. This 
suggests that NF-κB signaling activation is not the direct contributor to the LPS-induced 
inhibition of PPARγ transcription and adipogenesis. To further confirm this conclusion, 
we examined the rescue effect of NF-κB inhibitor on LPS inhibition of adipogenesis. As 
our results shown, NF-κB inhibitor (Bay 11-7082) failed to reverse the inhibition of 
44
adipogenesis by LPS in SV cells. Wang et al conducted similar studies in 3T3-L1 cells 
[104] and their results are not completely consistent with our findings. This discrepancy 
could be due to the differences in cell models and NF-κB inhibitors used in two groups. 
Wang et al used IKKβ inhibitor sc-514 instead of Bay 11-7082 to block NF-κB signaling 
activation in 3T3-L1 adipocytes. Most importantly, they observed that sc-514 only 
partially rescues LPS inhibition of adipogenesis. The differentiation rate was still 40-50% 
lower in cells treated with LPS plus sc-514 compared with control cells or cells treated 
with sc-514 alone. Thus, we conclude that LPS inhibits adipogenesis in part via a NF-κB 
independent mechanism.  
Zfp423 has recently been determined as a key regulator of adipogenesis. In a 
previous study, Zfp423 positive cells isolated from SV fraction of both subcutaneous and 
visceral adipose tissue of mice were able to stably commit to preadipocytes and 
differentiate into adipocytes [161]. Ectopic expression of Zfp423 in non-adipogenic NIH 
3T3 fibroblasts robustly promoted adipocyte differentiation [36]. In contrast, 
transcriptional repression of Zfp423 by Zfp521 inhibited the commitment of 
mesenchymal stem cells to adipocyte lineage [180]. In the present study, we showed that 
the expression of Zfp423 gene was significantly down-regulated upon LPS treatment in 
SV cells, and the downregulation of Zfp423 was not reversed by NF-κB inhibitor. These 
results suggest that Zfp423 could be the effector of LPS, leading to the inhibition of 
intrinsic adipogenic potential. A line of evidence from in vitro studies indicates that 
Zfp423 is an upstream transcriptional factor that enhances PPARγ expression, thereby 
controlling adipogenesis [36]. Our data consistently showed that LPS suppressed both 
Zfp423 and PPARγ expression simultaneously. In the meantime, PPARγ agonist 
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rosiglitazone was able to activate PPARγ and restore adipogenesis bypassing the 
activation of Zfp423 expression. Moreover, previous studies have shown that knocking 
down Zfp423 in 3T3-L1 preadipocytes led to the upregulation of C/EBPβ expression, but 
the downregulation of PPARγ expression [36]. We observed the similar changes in 
C/EBPβ and PPARγ expression in LPS treated SV cells in this study. All these data 
together led us to speculate that LPS inhibition of intrinsic adipogenic potential of 
adipocyte progenitor cells could be attributed to the suppression of Zfp423 expression. 
To confirm this speculation, further studies are needed to determine whether the 
constitutive overexpression of Zfp423 could protect against LPS inhibition of 
preadipocyte commitment and differentiation.   
In summary, the present study has added new knowledge of the differential role of 
LPS in adipocyte inflammation and differentiation. The effect of LPS in SV cells shown 
in this study indicates that LPS inhibits adipogenesis by disrupting the adipocyte 
progenitor cell differentiation which is independent of LPS stimulation of NF-κB 
signaling pathway and cytokine production. Additionally, LPS induces pre-mature 
senescence in a telomere-independent manner in adipocyte progenitors. Since plasma 
LPS levels are increased during HFD feeding and aging, our data suggest that LPS could 
be a potential contributor to the defective adipogenesis and the development of cellular 
senescence in adipose tissue during obesity and aging. 
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FIGURES
Figure 1. Effect of short-term LPS treatment on adipocyte 
differentiation in primary inguinal SV cell cultures. 
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Figure 2. Effect of LPS treatment on cellular senescence in 
inguinal SV cells. 
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Figure 3. Effect of LPS withdrawal on inflammatory response 
in primary inguinal SV cell cultures. 
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Figure 4. Effect of blocking NF- κB activation on LPS-
inhibition of adipocyte differentiation.
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Figure 5. Effect of LPS treatment on the expression of 
preadipocyte differentiation genes in SV cells. 
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FIGURE LEGEND
Figure 1. Effect of short-term LPS treatment on adipocyte differentiation in 
primary inguinal SV cell cultures. A: Schematic diagram of experimental design. B: 
Morphology (100 X magnification) of day 7 differentiated inguinal adipocytes with 
1µg/ml LPS treatment during different periods of differentiation process. C: mRNA 
expression of adipocyte marker and lipogenic genes in differentiated inguinal adipocytes 
with 1µg/ml LPS treatment during different periods of differentiation process. D: 
Dynamic change of PPARγ expression in day 0, day 1 and day7 differentiated inguinal 
adipocytes with 24h treatment of 0.2µg/ml LPS during day -1 to day 0. In each 
independent experiment, SV cells isolated from 3-4 mice were pooled and cultured in 6-
well plates. The 3-4 wells of cells were included for each treatment group. The 
experiment was repeated 2-3 times with different sets of mice. The data are represented 
as mean ± SEM. * p<0.05, compared with control.
Figure 2. Effect of LPS treatment on cellular senescence in inguinal SV cells. 
Confluent inguinal SV cells were treated with 0.2µg/ml LPS for 24 hours and subjected 
to the measurements of cellular senescence markers (A), β-gal activity (B) and staining 
(C).  Production of hydrogen peroxide (D), expression of senescence featured genes (E) 
and telomere length (D).  For telomere length and SA β-gal staining (C and F), 0.2µg/ml 
LPS was added to the cultures during serial passaging. The β-gal positive cells are 
indicated by red arrows (100 X magnification). 3-4 wells of cells were included for each 
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treatment group. The experiment was repeated 2-3 times with different sets of mice. The 
data are represented as mean ± SEM. * p<0.05, compared with control.
Figure 3. Effect of LPS withdrawal on inflammatory response in primary inguinal 
SV cell cultures. Confluent inguinal SV cells were treated with 0.2µg/ml LPS for 24 
hours prior to adding differentiation cocktails (day -1 to day 0). After 24h treatment, LPS 
was removed and cocktails were added to induce the differentiation. NF-κB activity (A) 
and gene expression of cytokines (B) were determined at day 1 and day 7 of 
differentiation. The levels of gene expression in panel B are presented as fold change 
relative to the levels in control cells on day 0 as shown in Fig 3E. The 3-4 wells of cells 
were included for each treatment group. The experiment was repeated 2-3 times with 
different sets of mice. The data are represented as mean ± SEM. (n=3 per group) * 
p<0.05.
Figure 4. Effect of blocking NF- κB activation on LPS-inhibition of adipocyte 
differentiation. Confluent inguinal SV cells were treated with 0.2µg/ml LPS for 24 
hours prior to adding differentiation cocktails (day -1 to day 0).  After 24h treatment, LPS 
was removed and cocktails were added to induce the differentiation. Bay 11-7082 at the 
dose of 3µM was added from 3 hours prior to LPS treatment to day 3 of differentiation. 
Gene expression of cytokines (A), protein expression of PPARγ and NF-κB p65 (B) were 
detected in inguinal SV cell cultures 24 hours after LPS treatment. Morphology (100 X 
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magnification) of SV cell differentiation was determined on day 7 of differentiation(C). 
D and E: LPS and Bay 11-7082 were added during the entire period of differentiation 
process (day -1 to day 7). Morphology (100 X magnification) of SV cell differentiation 
(D) and expression of adipocyte marker genes (E) were determined at day 7 of 
differentiation. The 3-4 wells of cells were included for each treatment group. The 
experiment was repeated 2-3 times with different sets of mice. The data are represented 
as mean ± SEM. (n=3 per group) * p<0.05, compared with control.
Figure 5. Effect of LPS treatment on the expression of preadipocyte differentiation 
genes in SV cells. Expression of preadipocyte differentiation genes (A) in SV cells upon 
LPS treatment for 24 hours. 3µM Bay 11-7082 or 1 µM Rosiglitazone was added from 3 
hour prior to 24-hour LPS treatment to day 3 of differentiation. The expression of Zfp423 
(B) in SV cells was measured after 24-hour LPS treatment. Morphology (100 X 
magnification) of differentiated inguinal adipocytes (C) with or without LPS in the 
presence or absence of Rosiglitazone treatment were determined at day 7 of 
differentiation. Rescue effect of Rosiglitazone on the expression of PPARγ (D) and 
senescence related genes (E) in inguinal SV cells treated with LPS for 24 hours. The 3-4 
wells of cells were included for each treatment group. The experiment was repeated 2-3 
times with different sets of mice. The data are represented as mean ± SEM. (n=3 per 
group) * p<0.05, compared with control.
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CHAPTER 3
KNOCKING DOWN NPC2 EXPRESSION REDUCES 
LYSOSOMAL ACTIVITY AND IMPAIRS 
INFLAMMATORY EFFECT OF LIPOPOLYSACCHARIDE 
IN ADIPOCYTES  
The manuscript authored by Ming Zhao, Hong Guo, and Xiaoli Chen is to be submitted.
Ming Zhao performed the experiments (Fig1A-G; 2A, C, D; 3B, C, E; 4A-F; 5A, B, D) 
and wrote this chapter
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SUMMARY
Lysosomal activity plays an important role in controlling inflammation. Niemann-
Pick disease, Type C2 (NPC2), an endosomal/lysosomal protein, is known to play an 
important role in intracellular transport of cholesterol. NPC2 deficiency leads to 
lysosomal accumulation of cholesterol. We previously reported that NPC2 expression is 
upregulated in adipose tissue in obesity. In this study, we investigated the role of NPC2 
in regulating lysosomal activity and inflammation in 3T3-L1 adipocytes by determining 
the impact of NPC2 knockdown (KD) on adipocyte inflammation and function. 
Compared with scrambled cells, NPC2 knockdown adipocytes had similar differentiation 
capability. NPC2 knockdown impaired lysosomal activity in adipocytes, as evidenced by 
the reduced mature form of lysosomal protease cathepsin B (CtB) and decreased 
autophagy-lysosomal degradation leading to the accumulation of LC3 and p62. 
Surprisingly, NPC2 knockdown diminished LPS-induced inflammatory response 
including NF-κB and ERK1/2 phosphorylation and the expression of pro-inflammatory 
genes such as TNFα, IL18, MCP1 and MMP9. The mRNA expression of ECM genes 
(FN, Col1, Col3, Col4 and αSMA) was down-regulated in NPC2 KD adipocytes under 
the basal condition when compared with scrambled controls. Moreover, NPC2 KD 
blunted LPS-stimulated glucose uptake in adipocytes. The normal expression of TLR2 
and 4 genes by LPS suggests that the reduced response to LPS was not due to the defects 
in the gene expression of TLRs. Our results suggest that NPC2 plays a role in regulating 
lysosomal activity and modulating LPS-induced inflammatory signaling pathway 
activation. Considering the similar structure of NPC2 with TLR co-activator MD-2, we 
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propose that NPC2 may mediate the binding of LPS to TLR4 which takes place in 
endosomes, thereby regulates inflammatory signaling activation.
INTRODUCTION
Our understanding of the role of adipose tissue in metabolism has expanded in the 
last decade. Adipose tissue is now considered as not only a lipid storage site, but also an 
endocrine and immunologically active site [181, 182]. Chronic low-grade inflammation 
in adipose tissue has been well-established as a trigger of metabolic disorders such as 
insulin resistance [53, 183]. There are several models proposed for explaining the cause 
of adipose tissue inflammation, such as oxidative stress, ER stress, and fatty acid 
overload. Lipopolysaccharide (LPS), a major component of the outer membrane of 
Gram-negative bacteria, has been recently considered as a critical stimulus of adipose 
tissue inflammation. The data from human studies has shown that obese subjects have 
altered gut microﬂora, leading to the elevation of circulating LPS [184]. In addition, 
circulating LPS levels were found to be increased in aged humans [155]. Consistently, 
high fat diet feeding led to an increase in the proportion of LPS-containing microbiota in 
the gut and LPS concentration in circulation in mice [185]. LPS has been known to bind 
toll like receptor (TLR) 2 and 4 on the plasma membrane with the involvement of MD-2 
to activate an immune response and induce inflammation [100]. Adipocytes and 
macrophages share many similarities in terms of their responses to LPS, since they both 
express TLRs, and secrete inflammatory cytokines and chemokines, such as TNFα and 
IL-6 [101]. In this sense, understanding the regulation of inflammation in adipocytes 
could be as important as that in macrophages.
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Aging is a risk factor for the development of chronic metabolic diseases such as 
type 2 diabetes, cardiovascular disease, neurodegenerative disease, and cancer. 
Continuous turnover of intracellular proteins is essential for the regulation of multiple 
cellular functions, thereby maintaining cellular homeostasis. Cellular aging is associated 
with the disruption of intracellular protein homeostasis, leading to the accumulation of 
damaged cellular components including oxidized and misfolded proteins and damaged 
organelles [186, 187]. The autophagy-lysosome system is one of the main intracellular 
proteolytic systems that are responsible for the clearance of unwanted intracellular 
macromolecules and organelles [188]. Induction of Autophagy-related genes (ATG) 
initiates the formation of autophagosomes. During the activation of autophagy, 
Microtubule-associated protein 1A/1B-light chain 3-I (LC3-I) is converted to Light Chain 
3-II (LC3-II) which can be recruited to the autophagosomal membrane to mediate the 
formation and elongation of autophagosomes [189]. In the next stage, p62/SQSTM1 
recognizes polyubiquitinated protein aggregates and delivers them to the autophagosomes 
via the interaction with LC3-II [190]. In the final stage, autophagosomes are fused with 
lysosomes, and the autophagic cargo is degraded by different hydrolytic enzymes in the
autophagolysosome [191]. Beyond removing damaged proteins and organelles, the 
autophagy-lysosome system also plays a critical role in regulating energy homeostasis, 
cell differentiation and defense against invading microorganisms [192]. In immune cells, 
it has been well documented that inflammatory signals stimulate the autophagy-lysosome 
activity [193-195], which can in turn clear pathogens and resolve inflammation. Although 
adipocytes act similar to macrophages in many ways in adipose tissue inflammation, the 
role of the autophagy-lysosome system in regulating inflammation in adipocytes has not 
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been clearly elucidated. Several lines of evidence have shown the concurrence of 
increased inflammatory cytokines (such as TNFα, IL-1β, IL-6, MCP1) and decreased 
lysosomal activity in adipose tissue during aging [149, 151, 196, 197], suggesting that the 
autophagy-lysosome system may play a similar role in regulating inflammation in 
adipocytes. 
Niemann-Pick disease, Type C (NPC) proteins, which are located in the late 
endosome and lysosome, consist of two major members: membrane bound NPC1 and 
soluble NPC2. The deficiency of either of them leads to a rare autosomal recessive 
disease called Niemann-Pick C disease, with symptoms including neurodegeneration, 
hepatosplenomegaly and pre-mature death [198]. More than 95% of the cases of 
Niemann-Pick C disease are due to a defect in the NPC1 gene [199], while the defects in 
the NPC2 gene are responsible for the remaining 5% [200]. Biochemical studies have 
unraveled that NPC1 and NPC2 function in concert to facilitate the export of unesterified 
cholesterol from endosomes and lysosomes [201, 202]. Therefore, either NPC1 or NPC2 
deficiency causes the accumulation of cholesterol and other cargo in the late endosomes
and lysosomes, which disrupts the normal lysosomal activity. Interestingly, several recent 
studies unveiled that NPC2 has some NPC1-independent effects. First, NPC2 transports a 
small portion of endosomal cholesterol to mitochondria in Chinese hamster ovary cells, 
where cholesterol is converted to oxysterols and steroids to maintain mitochondrial 
membrane structure and function [203]. Secondly, NPC2 is secreted into plasma, bile and 
epididymal fluid in rodents and humans [204, 205]. However, the level of secretory 
NPC2 significantly varies among different mouse strains, and the biological role of 
secretory NPC2 has not been well elucidated. Although the accumulation of unesterified 
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cholesterol in the late endosome/lysosome is commonly believed to be the cause of NPC 
disease, the physiological role of NPC proteins, especially NPC2 has not been fully 
understood.
While most of previous studies on NPCs focus on their role in nervous tissue, 
liver and spleen, few studies have investigated the connection of NPC proteins to obesity 
and insulin resistance. A single-nucleotide polymorphism (SNP) in NPC1 has been 
associated with obesity and type 2 diabetes, and genetic inhibition of NPC1 causes 
insulin resistance in adipocytes [206]. Less is known for NPC2. Our lab has previously 
reported that high-fat diet feeding upregulates the mRNA and protein expression of 
NPC2 in epididymal adipose tissue in mice [207]. Consistently, others reported that 
NPC2 expression is upregulated in subcutaneous abdominal adipose tissue of morbidly 
obese women compared to non-obese subjects [208]. However, the role of NPC2 in 
adipocyte metabolism and function and how NPC2 deficiency contributes to obesity and 
obesity-related metabolic disorders remains unclear. Considering the concurrent 
upregulation of inflammation and NPC2 expression in obese adipose tissue, and the role 
of NPC2 in lipid metabolism in lysosome, we hypothesized that NPC2 may play an 
important role in autophagy-lysosomal function in adipocytes, thereby regulating 
adipocyte metabolism and inflammation. In this study, we demonstrate that NPC2 is 
critical for regulating lysosomal activity; and NPC2 deficiency reduced the response of 
adipocytes to LPS stimulation in inflammatory signaling pathway activation and glucose 
metabolism.
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MATERIALS AND METHODS
Generation of NPC2 Knockdown 3T3-L1 Cells
The shRNA was generated with ViraPower Lentiviral Expression Systems 
(Invitrogen, Carlsbad, CA) by the Minnesota Obesity Center, University of Minnesota. 
Oligos of RNAi stem loops directed against mouse NPC2 were synthesized and cloned 
into a lentiviral-based RNAi vector pLKO.1. Two shRNA sequence variants for NPC2 
gene were synthesized and cloned into the vector pLKO.1.Recombinant lentiviruses were 
generated and tested for the efficiency. The selected oligomers targeting NPC2 sequence 
were 5’-GCTCTCGTTCTTTGGTAGTTT-3’, and 5’-
CGGTTGTAAGAGTGGAATCAA-3’. Recombinant lentivirus containing a scrambled 
siRNA sequence was used as a control. 3T3-L1 fibroblasts at 70-80% confluence were 
transducted with virus supplemented with 6 µg/ml polybrene (Sigma-Aldrich, St. Louis, 
MO) for 12 h. Cells were gently washed in PBS and cultured for 6 h before screening 
with 2 µg /ml puromycin (Sigma-Aldrich). Non transducted cells died after 7 days, and 2 
colonies of survived transducted cells were picked for testing NPC2 gene expression. 
One colony with good knockdown efficiency and differentiation capacity was selected 
for experiments.
3T3-L1 Cell culture
3T3-L1 cells were cultured in growth medium (DMEM plus 10% BCS) until two 
days after confluence. Cells were then differentiated with a differentiation cocktail (100 
IU/ml penicillin-streptomycin, 10% fetal bovine serum, 115 μg/ml 
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methylisobutylxanthine, 390ng/ml dexamethasone, and 1 μg/ml insulin) for 2 days. The 
cultures were then continued with DMEM with100 IU/ml penicillin-streptomycin, 10% 
fetal bovine serum, and 1 μg/ml insulin for another 5 days. Full differentiated 3T3-L1 
adipocytes were used for experiments. 100nM BafA1 was given for 24 hours to inhibit 
lysosomal activity and autophagic flux. 0.5µg/ml LPS was given for 24 hours to initiate 
inflammation.
Western blotting analysis
Proteins were extracted from cell samples using RIPA buffer (Sigma, St. Louis, 
MO, USA) containing protease inhibitors and phosphatase inhibitor cocktail. Equivalent 
amounts of proteins were separated on 8-10% SDS-PAGE gel and then transferred to 
nitrocellulose membranes. The membranes were probed with Cathepsin B& L, NPC2, 
NF-κB p65, phospho-NF-κB p65 (Ser536), ERK1/2, phosphor ERK1/2 (T202/Y204), 
MMP9, LC3, P62, Beclin-1, Atg7, Akt, phosphor-Akt (Ser473), or β-Actin (Cell 
Signaling, MA, USA) antibodies according to the recommendations of the manufacturers. 
ECL Western Blotting Detection System (GE Healthcare BioSciences, Piscataway, NJ, 
USA) was used to detect antibody reactivity. 
Relative quantitative real-time RT-PCR
Total RNA was extracted from cells using the Trizol method (Invitrogen, 
Carlsbad, CA, USA) according to the manufacturer's instructions. cDNA was synthesized 
from DNase-treated RNA (3µg) using a Superscript II reverse transcriptase kit 
(Invitrogen, Carlsbad, CA, USA). Real time-PCR was performed using SYBR Green 
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qPCR Master Mix (Qiagen, MD, USA) with an ABI Step One Plus real-time PCR 
System (Applied Biosystems, Foster City, CA, USA). Primer sequences are provided in 
Table 2. Results are normalized to TBP using the ΔΔCt method and presented as levels of 
expression relative to that of controls. 
Oil-Red O Staining
Differentiated adipocytes were washed twice with PBS and fixed with Baker’s 
Formalin at 4°C for 30 min. Cells were then stained for 10 min in freshly diluted Oil Red 
O solution. Finally, cells were washed with running water and observed under the 
microscope. 
Glucose uptake assay
Uptake of 2-deoxy-D-[3H]glucose (Amersham Biosciences, Piscataway, NJ, USA) 
was measured as previously described. Briefly, 3T3-L1 adipocytes were first treated with 
or without 0.5µg/ml LPS overnight before the assay. Cells were then serum starved in 
KRH buffer supplemented with 0.5 % BSA and 2 mmol/L sodium pyruvate (pH 7.4) for 
2 h before incubated either with or without 173 nmol/L insulin for 30 min at 37°C. 
Glucose uptake was initiated by adding 100 μmol/L [3H] 2-deoxy-D-glucose. After 5 min, 
cells were washes with ice-cold PBS buffer for three times and then solubilized with 
KRH buffer containing 1% Triton X-100. Incorporated radioactivity was determined by 
scintillation counting. 
Statistical analysis
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Results are expressed as means ± SEM. Differences in the parameters between 
two groups were evaluated using Student's t-test with a 0.05 2-sided significance level. 
One way ANOVA was used to compare the differences between multiple groups. A value 
of P < 0.05 was considered significant.
RESULTS
Role of lysosomal activity in inflammation in adipocytes
To investigate the role of lysosomal activity in inflammation in adipocytes, we 
used BafA1 to inhibit lysosomal activity and evaluated the effect of BafA1 on the gene 
and protein expression of lysosomal proteins (CtB and CtL), the gene expression of 
inflammatory cytokines, and the activation of inflammatory signaling pathways in 3T3-
L1 adipocytes. BafA1 is known to inhibit autophagy by impairing lysosomal hydrolase 
activity and preventing the fusion of autophagosome with lysosome [209]. Treatment 
with BafA1 for 24h led to an upregulation of CtB and CtL gene expression (Fig. 1A). At 
the protein level, BafA1 treatment completely blocked the maturation of pro-CtB as 
evidenced by a complete inhibition of the pro-CtB conversion to mature CtB (Fig. 1B). 
Interestingly, pro-CtB but not mature CtB was secreted into culture media; 
BafA1significantly increased pro-CtB secretion (Fig. 1C). BafA1 also stimulated CtL 
protein expression and secretion (Fig. 1B, C). BafA1 did not seem to significantly affect 
cellular NPC2 protein expression, but did slightly increased NPC2 secretion (Fig. 1B, C).  
To determine how inhibiting lysosomal activity affect inflammatory response, we 
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examined the gene expression of cytokines and inflammatory signaling pathway 
activation. As shown in Fig 1D, the phosphorylation of both NF-κB and ERK1/2 was 
increased after 24h treatment with BafA1. Moreover, the mRNA expression of TNFα, 
MCP1 (Fig 1E) and inducible nitric oxide synthase (iNOS) (Fig 1F) was significantly
increased, while the mRNA expression of extracellular matrix (ECM) proteins matrix 
metallopeptidase 9 (MMP9), collagen 3 (Col3), and α-smooth muscle actin (αSMA) was 
decreased (Fig 1G). These results suggest that inhibiting lysosomal activity by BafA1 
induces inflammatory response in adipocytes.
Generation of stable NPC2 knockdown 3T3-L1 cell line
To understand the role of NPC2 in adipocyte metabolism and function, we first 
examined the NPC2 gene expression during adipocyte differentiation. As shown in Fig. 
2A, NPC2 expression was increased by more than one fold during differentiation, 
indicating that it plays more important roles in mature adipocytes than in adipocyte 
progenitors. Next, we generated NPC2 knockdown 3T3-L1 cells to study the role of 
NPC2 in regulating lysosomal activity and its relation to metabolism and inflammation in 
adipocytes. 3T3-L1 fibroblasts were transduced with lentivirus containing the shRNA 
targeting NPC2gene. Transduced cells were selected after a screening period of 7 days in 
antibiotics puromycin. Gene knockdown efficiency was examined at both mRNA and 
protein level. As shown in Fig 2B, lentiviral shRNA was able to knock down the gene 
expression of NPC2 by 60% in 3T3-L1 adipocytes. Moreover, the protein level of NPC2 
was markedly reduced by more than 90% in NPC2 knockdown adipocytes compared to 
scrambled controls (Fig. 2B). To evaluate the possible effect of NPC2 knockdown on 
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adipocyte differentiation, Oil-red O staining as well as qPCR on gene expression levels of 
adipocyte markers were performed on scrambled and NPC2 KD 3T3-L1 adipocytes on 
Day 8 of differentiation. Oil Red-O staining results showed that both scrambled and 
NPC2 KD cells seemed to have similar differentiation capacity (Fig 2C). Additionally, 
the mRNA expression levels of adipocyte marker genes such as FABP4, C/EBPα and 
LPL were not different between scrambled and NPC2 KD adipocytes (Fig. 2D), whereas, 
the expression of PPARγ gene was decreased by 20% in NPC2 KD adipocytes (Fig. 2D).
NPC2 knockdown impairs lysosomal activity in adipocytes
NPC2 has been identified as an intracellular cholesterol transporter which acts in 
concert with NPC1 to remove cholesterol from the endosomal/lysosomal compartment. 
Previous studies on NPC1 function using NPC1-/- mice and cell models have 
demonstrated that there was a decrease in autophagy and lysosomal cathepsin activity in 
NPC1-/- fibroblasts, indicating that NPC1 plays an important role in autophagy-
lysosomal system [210, 211]. Herein, we investigated how NPC2 deficiency affects 
lysosomal activity in adipocytes. First, we determined the lysomosal activity in 
scrambled and NPC2 KD 3T3-L1 adipocytes by measuring the protein levels of cathepsin 
B expression. We found that there was a significantly reduced expression of mature form 
of CtB in NPC2 KD adipocytes (Fig. 3A). MMP9, which was significantly accumulated 
by BafA1 treatment (Fig. 3B), can be used as an indicator of lysosomal function. As 
demonstrated in Fig 3C, MMP9 was increased in NPC2 KD adipocytes compared to 
scrambled cells, suggesting a defective lysosomal proteolysis in NPC2 KD adipocytes. 
Since lysosomal activity plays a key role in autophagic flux, we then looked at the protein 
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levels of LC3 and p62 in NPC2 KD adipocytes under the basal state of autophagy. 
Interestingly, we found that both LC3-I and LC3-II levels were significantly increased in 
NPC2 KD adipocytes when compared with scrambled cells (Fig. 3D); so were p62 levels 
(Fig. 3D). However, other autophagy-related proteins such as Beclin-1 and Atg7 were not 
altered in NPC2 KD cells (Fig. 3E). These results suggest that the activity of lysosomal 
degradation is impaired in NPC2 KD adipocytes.  
NPC2 knockdown reduces LPS effect on inflammatory response in adipocytes
Autophagy-lysosome system has been known to regulate inflammatory response 
in immune cells. Our results from the experiments with lysosomal inhibitor above have 
linked lysosomal function to inflammation in adipocytes. We then investigated the effect 
of NPC2 knock down on inflammatory response in adipocytes. We showed that LPS 
treatment for 24h led to an increase in both the gene and protein expression of NPC2 in 
3T3-L1 adipocytes (Fig. 4A and 4B), implying that NPC2 may play a role in LPS-
induced inflammation. 
We next investigated how NPC2 knock down impacts the effect of LPS on 
inflammation. As shown in Fig. 4C, NPC2 KD adipocytes reduced NF-κB and ERK1/2 
phosphorylation in response to LPS stimulation compared to scrambled adipocytes. LPS 
treatment for 24h significantly stimulated NF-κB and ERK1/2 phosphorylation in 
scrambled adipocytes, but this effect was diminished in NPC2 KD adipocytes (Fig. 4C). 
Consistently, the LPS-induced expression of inflammatory genes including TNFα, IL18, 
MCP1 and MMP9 was also significantly attenuated in NPC2 KD adipocytes (Fig. 4D). In 
addition, we found that LPS did not seem to induce the expression of ECM genes such as 
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fibronectin (FN), Col1, Col3, Col4, and αSMA in scrambled adipocytes. Interestingly, the 
mRNA expression of these ECM genes was downregulated in NPC2 KD adipocytes 
under the basal condition when compared with scrambled controls (Fig. 4E). Moreover, 
LPS significantly upregulated the expression of ECM (FN, Col1, Col3 and Col4) in 
NPC2 KD adipocytes but not scrambled cells (Fig 4E). Additionally, LPS was able to 
stimulate TLR2 and TLR4 expression to a similar extent in both scrambled and NPC2 
KD adipocytes (Fig. 4F).
NPC2 knockdown diminishes LPS-stimulated glucose uptake, but does not affect 
insulin sensitivity in adipocytes
Our results have shown that NPC2 knockdown adipocytes have reduced basal 
lysosomal activity and inflammatory response to LPS stimulation. We then determined 
the effect of NPC2 knockdown on glucose metabolism and insulin sensitivity in 
adipocytes. As illustrated in Fig 5A, NPC2 KD adipocytes had slightly increased basal 
insulin-stimulated glucose uptake. Interestingly, 24h LPS treatment caused increased 
glucose uptake in scrambled adipocytes, but this stimulatory effect of LPS was completed 
blunted in NPC2 KD adipocytes (Fig 5B).  The treatment of 1 µg/ml insulin for 30min 
induced the phosphorylation of Akt at Ser 473 to a similar extent in both scrambled and 
NPC2 KD adipocytes (Fig 5C). Moreover, while the mRNA expression of  GLUT4 and 
adiponectin was not different between scrambled and NPC2 knockdown adipocytes under 
the basal condition, the mRNA expression of leptin was significantly reduced by more 
than 60% in NPC2 KD adipocytes compared to scrambled cells(Fig 5D). 
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DISCUSSION
NPC2 is known as a protein in the late endosome/lysosome, and functions as a 
cholesterol transporter in concert with NPC1. While most of the previous studies on 
NPC2 focused on its role in Niemann-Pick type C disease, the physiological function of 
this protein remains elusive. Our previous studies have suggested a connection of adipose 
NPC2 to obesity [207]. In a previous study from others, the role of NPC2 in adipocyte 
differentiation and function has been investigated using differentiated adipocytes from 
human skin fibroblasts as a model of adipocytes [212]. In this study, we focused on 
different aspects and investigated the role of NPC2 in regulating lysosomal activity in 
adipocytes, and the impact of NPC2 KD on adipocyte inflammation and function. 
First, we determined the effect of lysosomal activity on inflammation in 
adipocytes. Treatment with the lysosomal inhibitor BafA1 blocks the conversion of pro-
CtB to mature CtB, leading to increased pro-CtB accumulation and secretion in 
adipocytes. BafA1 also causes an increase in CtL, another lysosomal protease. Moreover, 
BafA1 treatment increases pro-inflammatory signaling pathway activation as evidenced 
by the increased NF-κB and ERK1/2 phosphorylation as well as the upregulation of 
TNFα, MCP1, and iNOS gene expression. These results suggest that inhibiting lysosomal 
function results in adipocyte stress and inflammation. In NPC2 KD adipocytes, we found 
that the mature form of CtB protein was reduced. The protein level of MMP9, which was 
increased by BafA1, was also upregulated in NPC2 KD adipocytes. Consistently, NPC2 
KD led to increased p62 and LC3 I/II protein levels under the basal condition, indicating 
that NPC2 knockdown impairs lysosomal proteolytic activity and function. Our results 
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are in line with the previous studies investigating the changes of autophagy in NPC 
disease. Both NPC1 deficiency and U18666A, which similarly inhibits the efflux of 
cholesterol from lysosome, led to enlarged autophagosomes, impaired autophagy flux and 
accumulation of ubiquitinated proteins in the endosomal/lysosomal compartment [213, 
214]. Therefore, our results support the fact that NPC2 plays an important role in 
maintaining normal autophagy-lysosomal activity.
In a recent study, NPC2 has been shown to contain MD-2-related lipid-
recognition (ML) domain; secreted drosophila NPC2a, a homologous of vertebrate NPC2 
in function, can bind to bacterial lipopolysaccharide (LPS) and modulate LPS effect on 
inflammatory signaling pathways [215]. However, similar effects of NPC2 have not been 
reported in mammalian cells. Therefore, we were interested in the role of NPC2 in 
mediating LPS effect on inflammation in adipocytes. We demonstrated that LPS is able 
to induce both the gene and protein expression of NPC2 in adipocytes, and NPC2 
deficiency impairs the lysosomal activity. We next studied how NPC2 deficiency affects 
LPS-induced adipocyte inflammation and function. Our results from the study of 
adipocyte cultures showed that 24-hour treatment of LPS significantly induces the 
phosphorylation of NF-κB and ERK1/2 in scrambled adipocytes, but fails to do so in 
NPC2 KD adipocytes. This suggests that knocking down NPC2 reduces LPS-induced 
inflammatory response. To provide additional evidence supporting this conclusion, we 
examined the effect of LPS on the gene expression of cytokines and ECMs in NPC2 KD 
adipocytes. We found that NPC2 KD does not affect basal levels of the mRNA 
expression of inflammatory cytokines and chemokines such as TNFα, IL-6, IL-18, and 
MCP1, but significantly reduces the mRNA expression of several ECM proteins 
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including MMP9, FN, Col1, Col3, Col4 and αSMA. More interestingly, NPC2 KD 
adipocytes have reduced response to LPS stimulation in the mRNA expression of 
cytokines. All the data together supports the fact that NPC2 deficiency impairs LPS effect 
on inflammation in adipocytes.  
It is of interest to investigate how NPC2 KD affects adipocyte metabolism and 
function. We then examined glucose uptake, insulin sensitivity and adipokine expression 
in NPC2 KD adipocytes. The basal level of glucose uptake was slightly increased in 
NPC2 KD adipocytes compared to scrambled adipocytes. Insulin is able to stimulate 
glucose uptake in both scrambled and NPC2 KD adipocytes at the similar level. 
Consistently, insulin-stimulated Akt phosphorylation was not different between 
scrambled and NPC2 KD adipocytes, suggesting that NPC2 KD does not interfere with 
insulin sensitivity. However, NPC2 KD diminishes LPS-induced glucose uptake in 
adipocytes, which is consistent with the earlier result showing that NPC2 KD blunted 
LPS induced inflammatory response. The similar levels of expression of TLR2 and TLR4 
genes between scrambled and NPC2 KD adipocytes in the basal and LPS-stimulated 
condition suggests that the effect of NPC2 KD on reducing LPS-stimulated inflammation 
may be through a mechanism independent of TLR transcription.  
There exist several lines of evidence that support a potential new model for the 
role of NPC2 in mediating LPS induction in inflammation. First, a previous study 
described the similarity between the cholesterol binding domain in NPC2 and the lipid-
recognition domain in MD-2, which is an extracellular binding partner of TLR4 and 
essential for the LPS-induced innate immune response [216, 217]. A later study on 
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secreted drosophila NPC2a, a homolog of vertebrate NPC2 in function, has shown that 
NPC2a functions similarly to MD-2; it binds to the lipid A moiety of bacterial 
lipopolysaccharide (LPS) and modulates LPS effect on inflammatory signaling pathways
[215]. It is reasonable to speculate that NPC2 has a similar effect in mammalian cells. 
Different from this secretory drosophila NPC2 model, we found that the majority of
NPC2 protein seems to be located intracellularly in 3T3-L1 adipocytes. We only detected 
a very limited level of NPC2 in culture media. Therefore, it is likely that the 
endosome/lysosomal NPC2, but not the secretory NPC2 is the major regulator of 
inflammatory response in adipocytes upon LPS stimulation. Indeed, there is an 
established pathway by which LPS triggers immune response in the endosome. Different 
from the TIRAP and MyD88 pathway, which mediates the signaling from TLR4 on the 
plasma membrane, internalized LPS and TLR4 in the endosome trigger inflammatory 
response via a different signaling pathway that involves TRAM and TRIF [218, 219].
These adaptors in turn activate the transcription factor interferon regulatory factor-3 
(IRF3), which regulates type I interferon (IFN) expression [220] and involves the late 
phase of NF-κB activation. The activated NF-κB is then translocated into the nucleus to 
initiate the transcription of pro-inflammatory cytokines. Based on our data and the above 
information from the literature, we propose that NPC2 may be required as a potential co-
activator for the activation of TLRs on the endosomal membrane and its signaling 
transduction to NF-κB pathway. Therefore, NPC2 deficiency blocks the activation of NF-
κB by LPS stimulation. To confirm this hypothesis, further studies are needed to examine 
the interaction of LPS, NPC2 and TLR4 in the endosome as well as the activity of 
TRAM-TRIF pathway in NPC2 deficient adipocytes. 
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In summary, we have demonstrated that NPC2 knockdown impairs lysosomal 
activity in adipocytes. We also found that NPC2 knockdown blunts LPS effect on 
inflammation and glucose uptake in adipocytes. We propose that NPC2 is an important 
regulator of the LPS-TLR4 signaling pathway activation that takes place in endosomes. 
Our studies indicate that NPC2 could serve as a potential therapeutic target for treating 
adipose tissue inflammation.
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FIGURES
Figure 1. BafA1 regulates lysosomal protein expression and 
induces inflammation in 3T3-L1 adipocytes.
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Figure 2. Generation of stable NPC2 knockdown 3T3-L1 cell 
line. 
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Figure 3. NPC2 knockdown impairs lysosomal activity in 
adipocytes.
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Figure 4. NPC2 knockdown reduces LPS effect on 
inflammatory response in adipocytes.
Fig. 4
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Figure 5. Effect of NPC2 knockdown diminishes LPS-
stimulated glucose uptake and insulin sensitivity in adipocytes.
78
Figure 6. A model of NPC2 role in LPS signaling in adipocytes.
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FIGURE LEGEND
Figure 1. BafA1 regulates lysosomal protein expression and induces inflammation in 
3T3-L1 adipocytes.
Fully differentiated 3T3-L1 adipocytes were treated with 100nM BafA1 for 24 hours. 
The mRNA expression of Cathepsin B (CtB), CtL, and NPC2 (A) were determined by 
real-time PCR. Protein levels of these three genes in cell lysate (B) and culture media (C) 
were measured by Western Blotting. 3T3-L1 adipocytes were either treated with BafA1 
or 0.5µg/ml LPS alone, or together for 24 hours. NF-κB and ERK1/2 phosphorylation 
(D) were determined by Western Blotting. The mRNA expression of cytokines (E), iNOS 
(F) and ECM genes (G) was measured in 3T3-L1 adipocytes after 24-hour BafA1 
treatment. The 3-4 wells of cells were included for each treatment group. The experiment 
was repeated 2-3 times with different sets of cells. The data are represented as mean ± 
SEM. * p<0.05, compared with control.
Figure 2. Generation of stable NPC2 knockdown 3T3-L1 cell line. 
Post-confluent 3T3-L1 cells were induced to differentiate into adipocytes. A: the mRNA 
expression of NPC2 in 3T3-L1 adipocytes on D0, D1 and D7 of differentiation. NPC2 
gene was knockdown in 3T3-L1 fibroblasts by shRNA. B: NPC2 gene (left) and protein 
(right) expression in scrambled and NPC2 knockdown adipocytes were measured by real-
time PCR and Western Blotting, respectively. Oil-red O staining (C) and the expression 
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of adipocyte marker genes (D) were detected in scrambled and NPC2 knockdown 3T3-L1 
adipocytes. 
Figure 3. NPC2 knockdown impairs lysosomal activity in adipocytes.
The protein expression of mature CtB (A) in differentiated scrambled and NPC2 KD 
3T3-L1 adipocytes was measured by Western Blotting. The MMP9 protein in adipocytes 
treated with 100nM BafA1 for 24 hours (B) or in scrambled and NPC2 knockdown 
adipocytes (C) were determined by Western Blotting. Autophagic markers LC-3, P62 (C) 
and Beclin-1, Atg7 (D) in scrambled and NPC2 knockdown adipocytes were measured 
by Western Blotting. The experiment was repeated 2-3 times with different sets of cells. 
The data are represented as mean ± SEM. * p<0.05, compared with control.
Figure 4. NPC2 knockdown reduces LPS effect on inflammatory response in 
adipocytes.
Protein (A) and mRNA expression (B) of NPC2 in differentiated 3T3-L1 adipocytes 
treated with 0.5µg/ml LPS for 24-hour. Scrambled and NPC2 KD adipocytes were 
treated with 0.5µg/ml LPS for 24-hour. NF-κB and ERK1/2 phosphorylation (C) was 
determined by Western Blotting; the mRNA expression of pro-inflammatory cytokines 
(D), ECM genes (E) and TLRs (F) was measured by real-time PCR. The experiment was 
repeated 2-3 times with different sets of cells. The data are represented as mean ± SEM. * 
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p<0.05, compared with control of scrambled cells, $ p<0.05, compared with control of 
NPC2 KD cells, # p<0.05, compared with scrambled cells treated with LPS.
Figure 5. Effect of NPC2 knockdown diminishes LPS-stimulated glucose uptake and 
insulin sensitivity in adipocytes.
Insulin-stimulated uptake of [3H]-2 deoxy-D-glucose in scrambled and NPC2 KD 
adipocytes (A) and glucose uptake in adipocytes with 0.5µg/ml LPS treatment for 24-
hour (B). Insulin-induced Akt phosphorylation was measured in scrambled and NPC2 
KD adipocytes (C) by Western Blotting. The mRNA expression of GLUT4, adiponectin 
and leptin in scrambled and NPC2 KD adipocytes was determined by real-time PCR (D). 
The experiment was repeated 2-3 times with different sets of cells. The data are 
represented as mean ± SEM. * p<0.05, compared with control, # p<0.05, compared with 
scrambled cells treated with LPS.
Figure 6. A model of NPC2 role in LPS signaling in adipocytes.
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CHAPTER 4
EICOSAPENTAENOIC ACID PROMOTES 
THERMOGENIC AND FATTY ACID STORAGE 
CAPACITY IN MOUSE SUBCUTANEOUS ADIPOCYTES
This chapter is modified from the published paper:
Zhao M and Chen X. Eicosapentaenoic acid promotes thermogenic and fatty acid storage 
capacity in mouse subcutaneous adipocytes. Biochemical and Biophysical Research 
Communications 450(4):1446-51, 2014.
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SUMMARY
In this study, we determined if eicosapentaenoic acid (EPA) promotes beneficial 
metabolic activities of subcutaneous adipocytes. Stromal-vascular (SV) cells were 
isolated from inguinal adipose tissue of C57BL/6 mice and induced to differentiate into 
adipocytes. EPA effect on thermogenic and mitochondrial gene expression and oxidative 
metabolism were assessed in inguinal adipocytes. When added to SV cell cultures during 
8 day differentiation, EPA significantly increased the expression of thermogenic genes 
UCP1-3, CIDEA and VEGFα. Moreover, EPA increased mitochondrial DNA content and 
the expression of genes involved in mitochondrial biogenesis including PGC1α, Nrf1 and 
COXiv. However, this effect was not evident when EPA was added to mature inguinal 
adipocytes for 24hr, suggesting that EPA exerts its browning effect via recruiting beige
adipocytes. Consistently, long-term EPA treatment also upregulated AMPKα 
phosphorylation and CPT1 expression and increased glucose uptake and GLUT4 mRNA 
expression, suggesting improved mitochondrial oxidation. Additionally, EPA-treated 
adipocytes had enlarged lipid droplets and increased expression of triglyceride synthesis 
genes GPAT1 and GPAT3, while significantly decreased glycerol release and down-
regulation of HSL and ATGL gene expression. We conclude that EPA enhances energy 
dissipation capacity by recruiting beige adipocytes to stimulate oxidative metabolism and 
reduces fatty acid release by facilitating fatty acid storage in subcutaneous adipocytes. 
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INTRODUCTION
Obesity is a serious health problem in the United States. Adipose tissue 
dysfunction, which occurs in obesity, is the major contributor to obesity-associated 
metabolic complications such as hypertension, cardiovascular disease, inflammation, 
insulin resistance, and type 2 diabetes. Two types of adipose tissues exist and exert 
opposite metabolic functions. Brown adipose tissue (BAT) is the major depot that plays a 
role in thermogenesis and energy expenditure, while white adipose tissue (WAT) mainly 
stores lipids and secretes metabolic regulators of adipokines and cytokines. 
In recent years, researchers found that brown-like adipocytes (beige adipocytes)
can be recruited in white adipose tissue in response to cold and β-adrenergic stimulation
[19, 20, 221]. This browning process is regulated by multiple transcription factors, co-
activators, and other molecular regulators, including PR domain containing 16 
(PRDM16), Peroxisome proliferator-activated receptor gamma coactivator 1-alpha
(PGC1α), peroxisome proliferator-activated receptor (PPARs), cell death-inducing 
DFFA-like effector a (CIDEA) and CCAAT-enhancer-binding protein-beta (C/EBPβ)
[41-43, 222]. More importantly, the browning process also potentially protects against 
obesity and insulin resistance [37, 223]. It has long been known that there exist depot 
differences in metabolic functions of WAT. Recent studies suggest that subcutaneous 
white adipose tissue (SC-WAT) has higher lipid storage capacity as well as thermogenic 
potential when compared with visceral WAT [43, 51]. These characteristics of SC-WAT 
may contribute to its metabolic benefits [140]. 
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Mitochondrion is a key organelle responsible for substrate oxidation and energy 
dissipation. Recent studies have emphasized the importance of mitochondrial function, 
especially in SC adipocytes in the development of insulin resistance [224]. In obesity, 
mitochondrial dysfunction in adipocytes leads to the production of toxic lipid species, 
inflammation and insulin resistance [225, 226]. Therefore, enhancing mitochondrial 
function and fatty acid oxidation, as well as increasing lipid storage capacity of 
adipocytes could lead to decreased release of free fatty acids (FFAs) from adipocytes, 
thereby preventing the circulating FFA elevation and subsequently metabolic 
deterioration. 
Polyunsaturated fatty acids (PUFAs) of the n-3 series have been known for their 
beneficial effects in regulating adipose tissue function. Three major members of n-3 FAs 
include α-linolenic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid 
(DHA). Previous studies on the metabolic effects of n-3 FAs showed that n-3 FAs are 
able to lower serum triglyceride (TG), reduce chronic inflammation, and increase insulin 
sensitivity in animals and human subjects [227-230]. The activation of PPARα, PPARγ 
and AMP-activated protein kinase (AMPK) could be the pathways that mediate the effect 
of n-3 FAs [231-234]. However, most of previous studies were performed in animal 
models or 3T3-L1 cell line without distinguishing the role of n-3 FAs in different fat 
depots.  
In this study, we specifically investigated the metabolic effect of EPA on SC 
adipocytes and determined whether EPA promotes beneficial metabolic activities in 
primary differentiated SC adipocytes. We found that EPA treatment during the process of 
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inguinal adipocyte differentiation significantly increased the expression of thermogenic 
genes and mitochondrial biogenesis/ function as well as TG storage. 
METHODS AND MATERIALS
Animals
Animal handling followed the U.S. National Institutes of Health guidelines, and 
experimental procedures were approved by the University of Minnesota Animal Care and 
Use Committee. C57BL/6 mice purchased from Jackson Laboratory were housed in 
specific pathogen-free facility at the University of Minnesota. Mice were allocated into 
groups (3 or 4 mice/cage) and fed a regular chow diet (RCD) with free access to water. 
Cell culture
Stromal-vascular (SV) cells were isolated from inguinal WAT of C57BL/6 mice 
as described previously [167]. After mincing, fat pads were digested with collagenase (2 
mg/ml solution) in Krebs-Ringer bicarbonate HEPES (KRBH) buffer. After 1.5h 
digestion, SV cells were separated by centrifugation at 1500 rpm for 10 min and then 
cultured in growth medium (DMEM plus 10% FBS) until confluence. Cells were then 
treated with a differentiation cocktail containing 10% fetal bovine serum, 115 μg/ml 
methylisobutylxanthine, 390ng/ml dexamethasone, and 1 μg/ml insulin for 3 days. Three 
days later, the differentiation cocktail was replaced with DMEM containing 10% fetal 
bovine serum, 100IU/mL penicillin/streptomycin, 1µg/ml insulin, and cultures were 
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continued for another 5 days. During 8 days of differentiation, 200µM EPA (EMD 
Chemicals, NJ, USA) was added to the cultures as fatty acid/fatty acid-free bovine serum 
albumin (BSA) complexes. The molar ratio of fatty acid to BSA was 4:1. FA-free BSA 
was used as a control.  
Western blotting
Proteins were extracted from cell samples in RIPA buffer (Sigma, St. Louis, MO, 
USA) containing protease inhibitors. Equal amounts of proteins were separated on 10% 
SDS-PAGE gel and transferred to polyvinylidene fluoride membrane. The membranes 
were probed with phospho-AMPKα (Thr172), AMPKα or β-Actin (Cell Signaling, MA, 
USA) antibodies according to the recommendations of the manufacturers. ECL Western 
Blotting Detection Systems (GE Healthcare BioSciences, Piscataway, NJ, USA) were 
used to detect antibody reactivity. The density of bands was quantified by Image J 
software, and the results were normalized to β-Actin of each corresponding samples.
Quantitative real-time RT-PCR
Total RNA was extracted from cells using Trizol reagent (Invitrogen, Carlsbad, 
CA, USA) according to the manufacturer's instruction. Real-time PCR was performed 
using SYBR Green qPCR Master Mix (SABioscience, Frederick, MD, USA) with an 
ABI Step One Plus real-time PCR System (Applied Biosystems, Foster City, CA, USA). 
Primer sequences are provided in Table 3. Results are normalized to β-actin using the 
ΔΔCt method and presented as levels of expression relative to that of controls. 
Mitochondrial DNA content
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Total DNA was extracted as previously described [24]. The samples were digested 
in lysis buffer (0.01 M Tris–HCl, 0.25 mM EDTA, 0.5% SDS, pH 8.3) containing 100 
µg/ml proteinase K and extracted with chloroform and 8 M potassium acetate. The 
supernatant was collected and precipitated with isopropyl alcohol and ethanol. mtDNA 
content was determined by detecting DNA levels of cytochrome C oxidase 2 (COX2) 
using real-time PCR. The value was normalized to the levels of nuclear genome DNA 
RIP140.
Glucose uptake assay
Uptake of [3H] deoxy-D-glucose (Amersham Biosciences, Piscataway, NJ, USA) 
was measured as previously described [9, 235]. Briefly, cells were serum starved in KRH 
buffer supplemented with 0.5 % BSA and 2 mmol/L sodium pyruvate (pH 7.4) for 3 h at 
37°C. Glucose uptake was initiated by adding 100 μmol/L [3H]-deoxy-D-glucose. After 5 
min, and the cells were solubilized with KRH buffer containing 1% Triton X-100 after 
three washes with ice-cold PBS buffer. Incorporated radioactivity was determined by 
scintillation counting. 
Measurements of glucose, lactate and glycerol levels
Glucose and lactate levels in cell culture medium were detected with Autokit 
Glucose (Wako, VA, USA) and lactate Assay Kit (Sigma-Aldrich, MO, USA), 
respectively. Media glycerol levels were detected with Free Glycerol Reagent (Sigma 
Aldrich, Saint Louis, MO) following the instruction provided by manufactures. 
Triglyceride content measurement
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On day 8 of differentiation, adipocytes were fixed in cold Baker’s Formalin for 30 
minutes at 4°C, followed by staining in Oil Red O for 10 minutes. After rinsing the wells 
with water, isopropanol was added to each well to elute the dye for 15 minute. Then the 
solvent was added into a 96 well plate and the OD was read at 540nm. 
Statistical analysis
Results are expressed as means ± SEM. Differences in the parameters between 
groups were evaluated using Student's t-test with a 0.05 2-sided significance level. A 
value of P < 0.05 was considered significant.
RESULTS
EPA regulates thermogenic gene expression in inguinal adipocytes
As shown in Fig. 1A, 8 day of EPA treatment had no evident effect on inguinal 
adipocyte differentiation. This morphological result was confirmed by the gene 
expression of PPARγ (Fig. 1B). Interestingly, 8 day treatment of EPA during the 
adipocyte differentiation process significantly increased gene expression of UCP1-3(Fig. 
1C). Similar effect was observed in differentiated brown adipocytes (Fig. 1D). In 
addition, EPA significantly increased CIDEA but not PRDM16 and C/EBPβ expression 
in inguinal adipocytes (Fig. 1E). Moreover, our results showed that there was a 2-fold 
increase in vascular endothelial growth factor α (VEGFα) in EPA-treated inguinal 
adipocytes (Fig. 1E). VEGFα is a key pro-angiogenic factor and its upregulation is an 
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essential process for thermogenic activation of BAT [236]. Taken together, our data 
suggest a browning effect of EPA in inguinal adipocytes.
Effect of EPA on mitochondria biogenesis and oxidation in brown and inguinal 
adipocytes
To evaluate the effect of EPA on mitochondrial biogenesis and oxidation 
capacity, mitochondrial DNA (mtDNA) content and mitochondrial oxidation gene 
expression were determined in brown and inguinal adipocytes. EPA treatment during the 
adipocyte differentiation process significantly increased mtDNA content in inguinal and 
brown adipocytes (Fig. 2A). Consistently, the expression of genes involved in 
mitochondrial biogenesis and oxidation such as PGC1α, Nuclear respiratory factor 1 
(Nrf1) and cytochrome c oxidase iv (COXiv) were significantly up-regulated in inguinal 
adipocytes when EPA was added during 8 day of differentiation (Fig. 2B). 
Mitochondrial function is an important factor that determines the fate of glucose 
metabolism, i.e. through mitochondrial oxidation or glycolysis. Therefore, lactate levels 
can be indicative of glucose oxidation level and mitochondrial function. As illustrated in 
Fig. 2C, EPA-treated inguinal adipocytes in the presence of insulin for 24hr had 
increased glucose uptake by approximately 30% compared to control cells. We also 
showed that the gene expression of GLUT4, but not GLUT1 was markedly upregulated 
by EPA treatment (Fig. 2D), suggesting that EPA increases glucose uptake by increasing 
GLUT4 expression. The glucose concentration in 24 hour cultured conditional medium 
was significantly lower in EPA-treated ingunal and brown adipocytes compared to 
control cells (Fig. 2E), which consistently reflects increased uptake of glucose by the 
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cells. However, lactate levels in the media were similar between control and EPA-treated 
inguinal and brown adipocytes (Fig. 2F). This implies that the additional glucose that has 
been taken-up into the cells is metabolized possibly through the oxidation pathway, 
supporting increased mitochondrial oxidation by EPA in adipocytes. 
To provide additional evidence supporting the enhanced mitochondrial function 
by EPA, we examined the EPA effect on FA oxidation. As shown in Fig. 3A and 3B, 
EPA treatment led to the upregulation of lipoprotein lipase (LPL), Cluster of 
Differentiation 36 (CD36), Carnitine palmitoyltransferase I (CPT1) gene expression, 
while down-regulation of acetyl-CoA carboxylase-alpha (ACCα) expression. Moreover, 
EPA treatment increased the phosphorylation of AMPKα at Thr172 residue (Fig. 3C). 
Together with an increase in PGC1α expression, all of these changes indicate an 
enhanced FA oxidation in inguinal adipocytes with 8 day treatment of EPA.
EPA treatment during the differentiation process increases lipid storage capacity in 
inguinal adipocytes 
We next determined the EPA effect on lipid storage capacity in inguinal 
adipocytes. As shown in Fig. 4A, EPA-treated inguinal adipocytes had significantly 
larger lipid droplets than control cells, which is consistent with the increased triglyceride 
content in EPA-treated adipocytes (Fig. 4B). Moreover, the expression of Glycerol-3-
Phosphate Acyltransferase 1 (GPAT1) and GPAT3 genes was upregulated by ~80% (Fig. 
4C), suggesting an increase in TG synthesis in EPA-treated adipocytes.  In addition to TG 
synthesis, lipolysis determines the TG content and lipid droplet size. Interestingly, EPA 
treatment reduced glycerol release into medium by 70% (Fig. 4D). This inhibitory effect 
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of EPA on lipolysis was only observed under the basal condition; EPA had no effect on 
norepinephrine-stimulated lipolysis (data not shown). In agreement with decreased 
glycerol release, EPA significantly inhibited the expression of HSL (hormone sensitive 
lipase) and ATGL (adipose triglyceride lipase) genes (Fig. 4E). However, EPA had no 
effect on perilipin1 gene expression (Fig. 4E). These data suggest that EPA promotes 
lipid storage capacity by increasing TG synthesis and decreasing lipolysis in inguinal 
adipocytes.
Palmitate and DHA had no effects on thermogenic gene expression in brown and 
inguinal adipocytes
Our results have clearly suggested that EPA increases mitochondrial function, FA 
oxidation, and lipid storage capacity in inguinal adipocytes. In terms of the specificity of 
EPA beneficial effect, we performed similar experiments using saturated fatty acid such 
as palmitate. Since chronic (8 day) treatment of palmitate is toxic to cells, we only looked 
at the effect of palmitate treatment for 24h in brown adipocyets. Unlike EPA, 24h 
treatment of palmitate had no significant effect on the expression of thermogenic genes 
including UCP1, PRDM16, C/EBPβ, and PGC-1α, while 24h EPA treatment significantly 
increased the expression of UCP1, PRDM16, and C/EBPβ in brown adipocytes (Fig. 
S1A). Furthermore, we conducted a similar experiment to examine the effect of DHA. 
Different from EPA, treatment of DHA during 8 day of adipocyte differentiation had no 
effect on thermogenic gene expression (Fig. S1B). DHA significantly inhibited adipocyte 
differentiation (Fig. S1C); this result is in line with a previous study in 3T3-L1 
adipocytes [237]. 
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DISCUSSION
Recent studies have demonstrated that brown-like adipocytes can be recruited in 
white adipose tissue, particularly in subcutaneous fat depot, which holds a potential to 
prevent obesity [223]. Herein, we sought to investigate the effect of EPA on metabolic 
functions of subcutaneous adipocytes focusing on thermogenesis and lipid storage 
properties. We found that EPA treatment during inguinal adipocyte differentiation 
increases thermogenesis, mitochondrial oxidation, and lipid storage capacity in inguinal 
adipocytes.  
N-3 PUFAs have been reported to increase the expression levels of UCPs in multiple 
tissues, such as brown adipose tissue, liver, and muscle [238-241]. However, few studies 
were focused on the browning effect of EPA on SC-WAT depot. In this study, we found 
EPA treatment increases the gene expression of UCP1-3 in inguinal adipocyte when 
added during the differentiation process. This, together with the up-regulation of CIDEA, 
VEGFα and PGC-1α expression, suggests the enhancement of thermogenesis and energy 
expenditure in SC adipocytes by EPA.
Mitochondrial function in white adipocytes determines lipid homeostasis and insulin 
sensitivity [224]. It directly regulates glucose and fatty acid oxidation, and also impacts
other metabolic pathways, such as lipogenesis, lipolysis and FA re-esterification. Hence, 
we determined the EPA effect on mitochondrial biogenesis and oxidation capacity in 
adipocytes. Our results showed that EPA increased mtDNA content and the expression of 
mitochondrial oxidation genes, such as PGC1α, Nrf1 and COXiv. Consistently, changes 
in ACCα and CPT1 expression, along with increased AMPK phosphorylation, suggest 
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that FA oxidation is enhanced in EPA-treated adipocytes. Our results are in agreement 
with previous reports that mice fed a diet rich in DHA and EPA had enhanced FA 
oxidation and mitochondrial function in adipose tissue [242]. Additionally, our result of 
glucose metabolism implies that EPA enhances glucose oxidation, which may result from 
the improved mitochondrial oxidation. 
The impairment of lipid storage function of white adipose tissue has been directly 
associated with the development of insulin resistance. The release of excessive fatty acids 
into the circulation due to decreased lipid storage capacity could be an important 
contributor to the ectopic fat accumulation and insulin resistance [140]. On the other 
hand, an increase of fat accumulation capacity in subcutaneous adipose tissue has been 
associated with the improvement of insulin sensitivity [243, 244]. In this study, we found 
that EPA promotes lipid storage capacity of inguinal adipocytes by increasing 
triglyceride synthesis and inhibiting lipolysis, which is consistent with previous reports 
showing that diets rich in fish oil reduces lipolysis and improves TG storage in adipose 
tissue [230, 231]. Taken together, our results suggest that stimulating thermogenic and 
oxidative metabolism of subcutaneous adipocytes, as well as increasing their lipid storage 
capacity, are some of the beneficial metabolic effects of EPA.  
It seems contradictory that EPA inhibits lipolysis and increases FA oxidation 
simultaneously in the same adipocyte. However, we hypothesize that EPA may affect 
lipid storage and thermogenesis in two different types of adipocyte, i.e. white adipocyte 
and brown-like adipocyte (beige adipocyte), respectively in subcutaneous SV cell 
cultures. On the one hand, EPA increases thermogenic capacity by increasing the 
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recruitment of beige adipocytes from adipocyte progenitor cells in white adipose tissue, 
and our data supports this notion. For instance, the effect of EPA on thermogenic gene 
expression was perceived only when EPA was added during SV cell differentiation, but 
not in fully differentiated inguinal adipocytes treated with EPA for 24h (data not shown). 
On the other hand, EPA promotes lipid storage in white adipocytes by inhibiting lipolysis 
and increasing TG synthesis. Further investigations are needed to test this hypothesis.   
In summary, our study provides evidence of a beneficial metabolic effect of EPA in 
inguinal adipocytes. Our results show that EPA induces mitochondria biogenesis, 
increases glucose uptake, and promotes oxidation of FAs and glucose. On the other hand, 
EPA enhances fatty acid uptake, lipid storage, but inhibits lipolysis, leading to decreased 
FA release. All of these changes together could be the mechanism by which EPA reduces 
inflammation and inhibits ectopic fat accumulation, thereby preventing insulin resistance.
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FIGURES
Figure 1. EPA effect on thermogenic gene expression in 
inguinal and brown adipocytes.
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Figure 2. EPA effect on mitochondria oxidation and glucose 
metabolism in inguinal and brown adipocytes. 
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Figure 3. EPA effect on lipid metabolism in inguinal 
adipocytes. 
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Figure 4. EPA effect on lipid storage in inguinal adipocytes.  
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Figure S1. Effect of palmitate and DHA on thermogenic gene 
expression in brown and inguinal adipocytes. 
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FIGURE LEGEND
Figure 1. EPA effect on thermogenic gene expression in inguinal and brown 
adipocytes.
Morphology of inguinal adipocytes (4X magnification) (A). Gene expression of PPARγ 
(B) and UCPs in inguinal adipocytes (C) and brown adipocytes (D) with EPA treatment
during adipocyte differentiation. Expression of thermogenic genes in inguinal adipocytes 
with EPA treatment (E). The results represent 2–3 independent experiments with 
different sets of mice (4-5 mice). White bar: control, black bar: EPA. The data are 
represented as mean ± SEM. (n=3 per group) * p<0.05, # p<0.1, EPA vs. control.
Figure 2. EPA effect on mitochondria oxidation and glucose metabolism in inguinal 
and brown adipocytes. 
Mitochondrial DNA content in inguinal and brown adipocytes EPA treatment (A). 
Expression of mitochondrial oxidation genes (B), uptake of [3H]-2 deoxy-D-glucose (C), 
and expression of GLUT1 and GLUT4 genes (D) in inguinal adipocytes with EPA 
treatment. The levels of glucose (E) and lactate (F) in the culture medium of inguinal and 
brown adipocytes with EPA treatment. The results represent 2–3 independent 
experiments with different sets of mice (4-5 mice). White bar: control, black bar: EPA. 
The data are represented as mean ± SEM. * p<0.05, # p<0.1, EPA vs. control.
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Figure 3. EPA effect on lipid metabolism in inguinal adipocytes. 
Expression of genes involved in fatty acids uptake (A) and fatty acids oxidation (B) in 
inguinal adipocytes with EPA treatment. AMPK phosphorylation in inguinal adipocytes 
(C). The results represent 2–3 independent experiments with different sets of mice (4-5 
mice). White bar: control, black bar: EPA. The data are represented as mean ± SEM.
(n=3 per group) * p<0.05, EPA vs. control.
Figure 4. EPA effect on lipid storage in inguinal adipocytes.  
Morphology (10 X magnification) (A) and triglyceride (TG) content (B) of inguinal 
adipocytes with EPA treatment. Expression of genes involved in triglyceride synthesis 
(C) in inguinal adipocytes with EPA treatment. The levels of glycerol in the culture 
medium of inguinal adipocytes with EPA treatment (D). Expression of genes involved in 
lipolysis (E) in inguinal adipocytes with EPA treatment. The results represent 2–3 
independent experiments with different sets of mice (4-5 mice). White bar: control, black 
bar: EPA. The data are represented as mean ± SEM. * p<0.05, # p<0.1, EPA vs. control.
Figure S1. Effect of palmitate and DHA on thermogenic gene expression in brown 
and inguinal adipocytes. 
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A: SV cells were isolated from brown adipose tissue of 4-5 mice and induced to 
differentiate into brown adipocytes.  At day 8 of differentiation, brown adipocytes were 
treated with palmitate (200μM) or EPA (200μM) for 24h. Cells were then harvested for 
thermogenic gene expression. B and C: SV cells were isolated from inguinal adipose 
tissue of 4-5 mice and induced to differentiate into inguinal adipocytes. DHA (200μM) 
was added during 8 days of adipocyte differentiation process. At day 8 of differentiation, 
adipocytes were harvested for thermogenic gene expression (B) or examination of overall 
morphologic differentiation (4X magnification) (C). The results represent 2 independent 
experiments.  The data are represented as mean ± SEM. (n=3 per group) * p<0.05, EPA 
vs. control.
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TABLE
        Table 1.  Sequences of Primer for Real-Time RT-PCR 
Gene Forward(5'--3')          Reverse ( 5'--3')
Adiponectin GCAGAGATGGCACTCCTGGA CCCTTCAGCTCCTGTCATTCC
C/EBPα AGCTGAGTTGTGAGTTAGCCATGT ACCCCACAAAGCCCAGAAA
C/EBPδ TTCCAACCCCTTCCCTGAT CTGGAGGGTTTGTGTTTTCTGT
GLUT4 AACGGATAGGGAGCAGAAACCCAA GTGCAAAGGGTGAGTGAGGCATTT
HIF-1α TCAAGTCAGCAACGTGGAAG TATCGAGGCTGTGTCGACTG
IL-1β AAATACCTGTGGCCTTGGGC CTTGGGATCCACACTCTCCAG
IL-6 AGAAGGAGTGGCTAAGGACCAA AACGCACTAGGTTTGCCGAG
LPL TGAGAAAGGGCTCTGCCTGA GGGCATCTGAGAGCGAGTCTT
MCP1 CTTCTGGGCCTGCTGTTCA GAGTAGCAGCAGGTGAGTGGG
PAI-1 TTCCAAGGCATCCAGAAGCAGAGA ACAGCAGCCGGAAATGACACATTG
PPARγ TTGACCCAGAGCATGGTGC GAAGTTGGTGGGCCAGAATG
Pref1 CAGGCAACTTCTGTGAGATCGTA TCGTTCTCGCATGGGTTAGG
TBP GAAGAACAATCCAGACTAGCAGCA CCTTATAGGGAACTTCACATCACAG
TNFα ACG CTC TTC TGT CTA CTG AAC TTC G ATA GCA AAT CGG CTG ACG GTG TGG
VEGFα CACGACAGAAGGAGAGCAGAAGT TTCGCTGGTAGACATCCATGAA
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Zfp423 GTCACCAGTGCCCAGGAAGAAGAC AACATCTGGTTGCACAGTTTACACTCAT
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        Table 2.  Sequences of Primer for Real-Time RT-PCR 
Gene Forward(5'--3')          Reverse ( 5'--3')
AdipoQ GCAGAGATGGCACTCCTGGA CCCTTCAGCTCCTGTCATTCC
C/EBPα AGCTGAGTTGTGAGTTAGCCATGT ACCCCACAAAGCCCAGAAA
Col1 CAACCTGGACGCCATCAAG CAGACGGCTGAGTAGGGAACA
Col3 AGCTTTGTGCAAAGTGGAACCTGG CAAGGTGGCTGCATCCCAATTCAT
Col4 GGCGGTACACAGTCAGACCAT GGAATAGCCGATCCACAGTGA
CtB TGAAGAAGCTGTGTGGCACT ATTGTTCCCGTGCATCAAA
CtL CTGCTTGGGAACAGCCTTAG GTTGCTGTATTCCCCGTTGT
FABP4 GATGAAATCACCGCAGACGACA ATTGTGGTCGACTTTCCATCCC
Fibronectin ATCACAGTAGTTGCGGCAGGAGAA TGTCATAGTCAATGCCAGGCTCCA
GLUT4 AACGGATAGGGAGCAGAAACCCAA GTGCAAAGGGTGAGTGAGGCATTT
IL-18 TCTTCTGCAACCTCCAGCATC GACATGGCAGCCATTGTTCC
IL-6 AGAAGGAGTGGCTAAGGACCAA AACGCACTAGGTTTGCCGAG
iNOS CACAAGGCCACATCGGATTT TCAATGGCATGAGGCAGGAG
Leptin CCACACACAGCTGGAAACTCC GGCTTGCTTCAGATCCATCC
LPL TGAGAAAGGGCTCTGCCTGA GGGCATCTGAGAGCGAGTCTT
MCP1 CTTCTGGGCCTGCTGTTCA GAGTAGCAGCAGGTGAGTGGG
107
MMP9 TATTTTTGTGTGGCGTCTGAGAA GAGGTGGTTTAGCCGGTGAA 
NPC2 ATACTTGGTTGCAGGTGCTTGG ACGCAGGAGTGGCAAGTTAGAA
PPARγ TTGACCCAGAGCATGGTGC GAAGTTGGTGGGCCAGAATG
TBP GAAGAACAATCCAGACTAGCAGCA CCTTATAGGGAACTTCACATCACAG
TLR2 TTTGCTGGGCTGACTTCTCT AAATCTCCAGCAGGAAAGCA
TLR4 GGCAGCAGGTGGAATTGTAT AGGATTCGAGGCTTTTCCAT
TNFα ACGCTCTTCTGTCTACTGAACTTCG ATAGCAAATCGGCTGACGGTGTGG
αSMA ATTGTGCTGGACTCTGGAGATGGT TGATGTCACGGACAATCTCACGCT
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Table 3.  Sequences of Primer for Real-Time RT-PCR
Accession No. Gene Forward(5'--3')  Reverse ( 5'--3')
NM_133360.2 ACCα ATGACAGTCCTCTTCCCATGCACA ACACTGTTCACACGACCCTATGCT
NM_025802.3 ATGL TGTGGCCTCATTCCTCCTAC TCGTGGATGTTGCTGGAGCT
NM_007393.3 β-actin GCTCTGGCTCCTAGCACCAT GCCACCGATCCACACAGAGT
NM_001159558.1 CD36 TCTTGGCTACAGCAAGGCCAGATA AGCTATGCAGCATGGAACATGACG
NM_009883.3 C/EBPβ AAGCTGAGCGACGAGTACAAGATG CTTGAACAAGTTCCGCAGGGTGCT
NM_007702.2 CIDEA TGC TCT TCT GTA TCG CCC AGT GCC GTG TTA AGG AAT CTG CTG
NC_005089.1 COX2 TCTCCCCTCTCTCTACGCATTCTA ACGGATTGGAAGTTCTCTATTGGC
NM_009941.2 COXiv ATGTCACGATGCTGTCTGCC GTGCCCCTGTTCATCTCGGC
NM_009948.2 CPT1β TCTAGGCAATGCCGTTCAC GAGCACATGGGCACCATAC
NM_010046.2 DGAT1 CTC TGC CAC AGC ATT GAG AC TGC TAC GAC GAG TTC TTG AG
NM_011977.3 FATP1 CGC TTT CTG CGT ATC GTC TGC AAG AAG ATG CAC GGG ATC GTG TCT
NM_011400.3 GLUT1 TCAACGAGCATCTTCGAGAAGGCA TCGTCCAGCTCGCTCTACAACAAA
NM_009204.2 GLUT4 AACGGATAGGGAGCAGAAACCCAA GTGCAAAGGGTGAGTGAGGCATTT
NM_008149.3 GPAT1 AGCAAGTCCTGCGCTATCAT CTCGTGTGGGTGATTGTGAC
NM_172715.3 GPAT3 CTTTGAAATCGGAGGAACCA TTTGCAAACTGAACTGCGTC
NM_001039507.2 HSL AGGTGGGAATCTCTGCATCACTGT TGTCCCTGAATAGGCACTGACACA
NM_008509.2 LPL TGAGAAAGGGCTCTGCCTGA GGGCATCTGAGAGCGAGTCTT
NM_010938.4 Nrf1 CCACGTTGGATGAGTACACG CTGAGCCTGGGTCATTTTGT
NM_001113471.1 Perilipin1 GGCCTGGACGACAAAACC CAGGATGGGCTCCATGAC
NM_008904.2 PGC1α ACCGTAAATCTGCGGGATGATGGA AGTCAGTTTCGTTCGACCTGCGTA
NM_011146.3 PPARγ TTGACCCAGAGCATGGTGC GAAGTTGGTGGGCCAGAATG
109
NM_001177995.1 Prdm16 AAGCTGTGCATGGCTCGTGTTTAG AGTCACCAGGAACTGTGGTCCATT
AC_000038.1 RIP140 TCCCCGAACACGAAAAGAAAG ACATCCATTCAAAAGCCCAGT
NM_009463.3 UCP1 ACTGCCACACCTCCAGTCATT CTTTGCCTCACTCAGGATTGG
NM_011671.4 UCP2 TGACAAACAGGTCAAGAGAGGGCA TCAGGCCAACTGACAGCATTCCTA
NM_009464.3 UCP3 GCAAAGCACAGGACCAACTTCCAA ATTCTGTCCTTCCACCATGTGGGT
NM_001025257.3 VEGFα CACGACAGAAGGAGAGCAGAAGT TTCGCTGGTAGACATCCATGAA
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SUMMARY
In the thesis, we used adipocyte culture model to investigate regulations of 
inflammation and adipocyte metabolism from several different aspects. We found that 
LPS treatment to SV cells inhibited adipogenesis, which may due to the impairment of 
the adipocyte lineage commitment of adipocyte progenitor cells. We also demonstrated
that endosome/lysosome protein NPC2 plays an important role in mediating LPS-induced 
inflammatory response. Since the structure of NPC2 is similar to TLR co-activator MD-2, 
we speculate that NPC2 may facilitate the binding of LPS to TLR4 in endosome, which 
in turn activates TRAM/TRIF pathway. In addition, we explored that EPA treatment 
induced the appearance of beige adipocytes features in subcutaneous adipocytes. This 
could increase energy expenditure, prevent inflammation and ultimately improve 
adipocyte metabolism. Overall, our studies expanded our understanding of the regulations 
of adipocyte inflammation and the consequent effect on adipocyte metabolism. Our 
results shed some light on the new therapeutic targets for treating adipose tissue 
inflammation and metabolic disorders. However, due to the limitation of time, we 
couldn’t study all the details of the mechanisms. Further studies are needed to verify our 
hypothesis that arose from the observations in these studies, such as the mechanism by 
which LPS disrupts adipocyte commitment and the role of NPC2 as a co-activator of 
TLR4 in endosomes. 
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